var title_f16_25_16784="Echogenic fetal bowel";
var content_f16_25_16784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echogenic fetal bowel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 251px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD7AZcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Uor7n/Z18IeGtT+DXhy71Lw7o93dyLNvnuLKKR3xPIBliuTwAPwr5T+Olnbaf8W/E9rYW0NraxXW2OGFAiINq8BRwKAOEooooAKKKKACiiigAooooAKKKKACiiigAoopR1oASivcPB+hXyfD/RdX8M+HNG1aRzML6TUREQjq5wPnYfw44H9a5X41T211qujT21hp1i8umwyzRWFusMfmMNxwB9cfhQB54kbOCVBIUZOB0HqaZWrousXmlw30FpO0UN9Cbe4AUHehOccjj8KpywBVDI24EZ47exoArUU4qw6ikxQAlFLSUAFFFFABRRRQAUUUtACU6NGkdURSzE4AAySackbOQAOtaeiX1zoWp2+pWkvlXlu26I7QcHp0PFAGUw2mm1PeTtc3Mk7nLyMXY+pJyT+dQUAFFFFABRRRQAUUUUAFFa3hTSf7d8S6XpXmiIXlwkBkP8IZgCa9B1jw5oOnx3+tWmk/2jpQNvHYW0VzMplR2lRp5MgOG3RbcYVdxGMjAIB5RRXo2t6Romn+CpJrvR5dM1OYFrAS3Ty3MmJsMZE2hEQLuUZAYsvHGcedN1oAVW2sCOoOa9Uk1mC68d6JrTyabcT22nafM0kl0ttFFMpjDZCqc45BRRkDJx8tedwxofD11IUUuLqFQ2OQCkuRn8B+VZ1AH0FYa/p6a/PNqGuLPdtFCJoptVWZbeESSGVEucYmQrsZoAPm3Y/hxXO+B73SdOtEP2qxtFkuorjUC1wg+12AMwkTZ2z8n7jluhwcjHj+T60ZPqaAPT/Feozy/DG3tb/WbC9kF1byWkUF0ku2EQuNoiABgKcBsj5ye+MnofEWh+BtGubjz7WwFzb28rx2a38mZiIEYeZk5R/MJCqD8wJ4OAa4T4SeH7LxL4pksdTtrq5t1s55tlucNuVflOcjuR9SR2zXcat4P0G6n8V/Ldz3mnXMm/7Rcv8AaAfMVLeJM5V1kBC7mywyPTkA474l2vhy2e2PhZIERbm6gkENyZg6Iy+XIck4zubGOMAdcEkqH4k2GjaddWdrpdrHZ6hH5q31tBcSXEURDDYvmP8AecDIbb8ucY70UAfXv7NzEfBTw1gn7k/f/pvJXyZ+0B/yWXxZ/wBfh/8AQRX1B+zycfBzw7z/AAzd/wDpvJXy18dv+SveKP8Ar7P/AKCKAODooooAKKKKACiiigAooooAKKKKACiiigApRSUUATR3M0QxFLIgznCsRVlrW8mjt5Jlm8uZT5UkgO1gDg4PoDxVEDNbemo0MQeKRi4UlgvUe2KAM+S0aKXZJx/tA8YpstvJHIAqn14Fdmk1lrsEcU6R2t4i4DgjDA9v/wBdZN/ZXmnXW14GkEfRohwfc0AYRuPMcmZcseMjipHjt3AKPg+jDH61o3MVndhUQeTLgnzNpw3saqT2UlvGdpWRcgZGP0oAqtakHAVsnkdDTGtpFA3KRn14qdLW4ZMrkg84ziiCK5abyzJ5bdPnbj6UAVPLbP8A9el8snp/MVfjtb3cCpQdfmJGKaGmjkImG3J7IMUAUvKbJBwCPU05YGIHB684HSrQMxlbymAVs4ywHHWmm3upmLKGYsM/Kc5oAiFvtP7whe/zcZpUaFFyVLPn8KebdBHiR387ONpXgevNXcC0tsxRIPM43OA5Prg9hQBnrNK5xEAhA5K/1pEgdmwTjIyfarNm8nm+VBHumY8HFdPp/h2WYxFp4VD/AHwDuOOnNAHN2+lGZiqtuI5yP88VX1PTrnTZkjuo2QugkQkcOpJAYeoyD+Vd/b2KR3ItdLgEspAzK3CRH1J71U1vQPtlizwy+fdx7j8o+UY+9k/yx3oA8+opWBBIIwaSgAooooAKKKKAOl8B6ZZalqd62ptdrb2VjNekWrqkjGMZADMCB+Ven3EOkf8ACWyvo3iLxBfahOzWy6ideggFwFjiOwSMnzH96F25/hNeefC2a0XxHcWl/FqEsOoWU9ltsIhLNl1xlVJA4wTXsPiTxF4egm1iS+/4S3Tba5nVNQtxYwCNxJCqCPknG5YWIdefvYNAC+JPCNhp6DQLzW/F9zpcccD3sZvovKtxNKVi+Qp+8zIDnHTrXnx8PeBTZWc6x+KVeWIyzLLJFGsGMEDeY8NlW3Aj+HBrsL74jeBr68E91e+I3Rtizwi0hCzxxSGSBCd2QIyeoILAfMTUGp+PPAGoaDomlS3HiFYdKiMMbi1i3SDCjLfPj+EdKAI7LwZ8OWtL60OvaosUt8ba1lDLKlw6ABXR0i2jcZCuCff3HhLZyc9a9+uPGvg271K41q11LxDAtvdvfG1+xQNF5ku1SQrMQDhcbuoBODXgJ60AOjUMwBOATjJ6Cu8tfh9byeJY9Hk1+FpJre3mt5La0lm8/wA5Qw2qACFAOSzY47enAV3OnfEGS2F0txpNrcxXNhbadIplliby4VCj50YN82BuGcHAoAuweAdasAW0TUFm1kKM2toSGaGVmjVlk4DbsH5fQ/UVHJ4b+IblYJbbVisty18FM3ytOAGM33sFsc7vY+hxFp/xJvNPFsbbTrNZIQsXmEuS8CFjHCfmxhS33gNxwMk85hX4h3y6Tc2H2O22T2kdoXy24Klv5AI56kc/WgCt45j8WrLZ/wDCaPqTyEP9n+2yF8YIDAZJxzg+4wehBoqv4u8WXHiYobu3hhK3VxdDyiesxUkcnoNoxRQB9U/ARlHwl0DJGdsvf/ptJXzP8befit4lI/5+j/6CK+hvge6D4WaECyg7Zep/6bPXzr8YyD8T/ERByPtJ/kKAOMooooAKKKKACiiigAooooAKKKKACiiigApVGWFJVqxt/PmAbPljlsfyoA17LSxYXzx6xA4Ayg2MDg+oYZDD6GtabRp7UedbDKdVbO1sE+9amkKklobeZXktQP3WTlo8A9Pb2NLd2jxMpjIYNtJJfORj1oAypNGlkw6oyTbuVORk/jzUunapd6bObeVAwG4NGw4x0IBrS/tYqqLKZJxCOjdcf7J/xqPUX8+EHyU67gSADyOenWgCsLCxuJw9lIGJj+eGQAH3x+dUtQ00REIhuYnC/MJExu9x+nNbWjHTDLGtzIYySSRsxxxzmornUBEzI8gvIY3wnmEkgfz6UAc9Dax3bot3KyOG2gkYI98VauNAnUJ5E8dxF2BJXP4H3rZg1W2+8pG4EhcDJAJ7Z60l5qi5VQA8SklnPBY/SgDnmsry3Hzxi22g4yOHJ6j6VRl/fYFxhCTwqjj8q6+31G1uEJkt4buVFJYPu5HTg1TNzpn2mRZdHRUIztSRhtI789aAOS8mOEhlzJ2KkVYjhkKqsSuhznK13FvqFjFE4j0u0VjwryOXPX9Ktrqoihj/ALNsQrEMCXQOPw6k0AclF4c1CS0ikbT5EkflZCcBl9a2NO8JLcpLNqd9DaRR8Mu4cH/PcZqZ9T1SWTZIu10OcJhcHoOMZH0pIrNri5LXqYLA53tjPuP8igCEy6bpEuNKhaZ1GDMeA39cU1dSvNS/dHy41CZEaKFCr6e/41ftrGC8+a4n2oOMqnRvcHr/APXq9p11Y2BylokzpnPmNgEj+In+goApWUVxJp4jFyEt925gyldxHTP0qzNelbKS3Zv3QTg7OMZ6ewzVnfJqczNvygwWjhIHB7AGj+z4JbWZnISKJs/ewWA6DP580Aee+ItJby5dRtkX7KriNyGAOTnBx17HJ/xrm69F1+VZYzHFHEsODhEHyj/E1wV5btbyYIwp5U+1AFeiiigAooooA6DwVq1rpOqXBv8AzFtbu0ms3liUM8IkQrvUEjJHpkcZr0jQPHXhrTNIj0qae5ubSzEKCSSwSQ30am4aRCrMfLDeaEDZyAe1cR8KT/xVgVbOO7ke2mWNWMRaNipxIiy/I7L1CnrXa6t4U8Opb3+p3Vxb3k8d+3mzWk8cMDyC4CfZVhGSN0ZL7wSB05AoA8euGV5naNdkZYlVznaD0FRV6r8Vjpk2jXEmm2NtBLD4ivoHeGROECoEG1QMKQvy9htPXcayfEWiRaz8TBp9qYbe0aC2knljACQxLbRtLIcccAMT7+9AHKaUd2n6vGfu/Z1k/ESoB/6Eay69i0rXtJvvD/ijUo7GzhOnRTw21sYly8E6xwxE92KGNSW7FieSa8ePBNACUUUUAFFFFABRRRQB9V/BmVF+GmihnAO2Xj/tq9eBfFohviPr5ByDcnn8BXtXwkmjX4e6QGcAhZOP+2r14h8UGDfEDXCpyDcH+QoA5aiiigAooooAKKKKACiiigAooooAKe0bqqsysFYZUkcEdOKaDg10Vz4gs7jwvHpB0iJJYpPMiulmYshON3BzwcdKAMfTbT7bLJGJVSQIWjUqSZGyPlGAcHGTk4HFdtp2jQW9im0rIVcFmByGGOuKp+DbVtPkS9O5Lh8+WSufl/xrqIr6AXH2kxOpVv3iggBxnnA7UAM1HSpIPKlTGJM4WI5zx6VVuYXikWOaTys5KsxyOe5A/nXSWeqWcSxpbQSsgy6KzDI/LpWJrMkd1dtLEhVCCUjdvmT1ye4oAhlsoIHidp45icsHUg/SpX02W4t0nt8D1BIIznse1BsLV4ojJEYVAUMVBIyR6f0q7Y2enQRtILho1bOCH+XPoV6ge9AGBHFaJc7rrf5mdrL396tXWm2s2P32FyfLIHI9j3rQNrY+aWliy4GVYdGBPB+tVbmGALhGTBbaM9Bk9c+tAESeHpBFn7VbqygbZBnDA9BxVG50S9jvHWaAFTwGwSHwM5H+NdDptrGwEe1pATh33DjHp60jtBa3zKjrbpGSBI2TgdDQBzdvaIs24HZtPy5GGNSRQys4leNnlViASMqAfrXSpqtpHHufEuGyHWJdpOP5ZogkgmcmJ2kA+by1B69cHnkUAU4dFu3S3ld1aKX5DvYcc9/896nSzsQ+DcBkxl1QN8mPXFXhbyRAyEIqEAqki8k//W9KrSrbohJkw5QsCqZ3c/oKAGfuo7kuixx/N8shz3HBJ6motQmllA8yETEcFkGD069PbpUsNzbKmVjhQq23aznIx3qtcXYL+ZGz3Ebk7j0Oe+P/AK9AFWa6miUxxQ/KxBDMP4ew+tR2mhahOPtE8EozlhxyR1Py/SrH2x/MdbSEMCMHcQcEc/lUcuq3MsbiWRnVehGQoz1/CgC7FItt5i2xjRQRu3nGPy9PWqGqamZFMSgJhMbmHTnms+7vNiRpBs8s8Btv6VRnuU81mLZPZu9ADfs/nBwHAXZkMap/2el1cR21zP5S9BIyEhP9ogc4+gq/cNv8pLeNVTaDgck1E1q7RZadljJwSefwoA5ORWRyrKVIPINNre1jTiVaWAl/LGG46qO9YVACUUUUALRk1Z0uxn1TUrWws1DXNzIsUaswUFmOByeBXZf8K0vkhubm51bTLexh8si6kE+xw+/BCiMuuDG4O5V6Z5BBoA4TJ9ackjpnYxXIIODjI9K6/wAN/DzWNftGvIAltYb9kd1cpIscuFkYlCFO4ARnOOeR61z/AIj0ifQdaudNupIpJoCMvESVYFQwIyAehHBAI6EA0AP0E72v4mPyyWcufX5RvH6oPwzWWTkk10ngLSpNX1S9hjmgt0jsLiSWaYtsjTYQWO0E4yw6A1FqPha5stEn1U3mnz2sN99gP2e4EjFsMQ4A/gIQ4JxntQBz9FbN54cv7YWC7POnu7Q3wgiBaSOIbjucY4+VS/8Au4JxRfeH7iz8O6drUk9q9rfSyRIkUod0ZApO8D7pww4PPt0oAxqK7Wz+Hl7czvbNqmlQX6wrL9kllYS5MfmbSApC4XGSxCgnGc5xgx6FcNo9pqLywRQ3V0bWESvtLEAFn54CLuUEk9T7HABkUV0PijwvLoEdlKdQsL+3uw/lTWjMVOwgN95VJHIwwBB7E4NFAHs/wuljXwHpQZwCBJ/6MavG/iOQ3jnWCpyDOefwFepfDqaNfBemqzYID/8Aoxq8p8fMG8Y6qVOQZv6CgDn6KKKACiiigAooooAKKKKACiiigArQsoLd4oXZ3abzSHjKfKEwMHdnkk5GMdhzzVFFLMAATWnBCURFC733cYFAGw93L5Y3TBo4/u8A8/zrpdE1C1i2i+RpMjhozgj/ABrj0UOzBlbGMdMc/StW2i8yPlZFIAYcelAHdHRIp7ctZ3Ec1vIC4OSJBjnkdsVVm0V4J5Jb1HlTZkSqP4SOM1nWJljQPbsssZXOz+IH6/0re0zXrpkEXmJvT5huPHpgen0oAxGjjwrlpHjQ8EttViehx9KfJHbPEy26oG6AqcEdyfcVtw6zBw01lDIrHYGJwCO/X7pqO6OmxPJ9nkb5lDmOQcH1OenagDCSFrhTGJismPlD8Y9s+hyaYSIoplljRmzkDHHTp/8AXrXWK1eEsXZwp2qwXnBOc8dv8arXFlbNFHI8b7snd149/wCXFADZbqNbdN8QeADKtngH+dMV4bhSdqEAfMDzs47Z/CtNLW3tblgQJBtHKng8dPbmqsdpb3jxxxymKQttaQgHcMnn6igDOhJWQxiGDzUcKo6joD6dKt3GqzSSTMiwwSDBPlLwB6fhUN/B5Usiy7I5uvDYx26e9LZW07ySbbpGiVc7mZUPI680AJJdzfZ97SiQyEZIy20+p96pSXpUxBwyxkFdxG4jryPSrl3bCLcsjW8zsdwKsX49M+9VJhbpApiRgxyMOc9+o9qAKLuzDDMApzzjOaIZFKDfL5YJ5DNwMe1RyqmV2gbRw2D3qvJbRvecEBSxJJ78UAW5tXVIwYMnH8eMVVv7uVo0jknYn+4iYH1zSMEibbCBIc9/4T7VWlEYQq5JkHK8YGfrQBCb8R52jPtjP5U1x5oUkjDZODnirFvh8hURd4xk46fSl+xfacFE+6OPmz9aAKf2hrd1eCQhc4HHIHerD6o0rp5hVokyQgXGTiqU2CxCvjOKaqqzH5yuBx359KANV7xJIGkZhEmMYA5c+n0rC1i2ghuAbNpHgdVYF49hDEZK4yeAcgHuOeKthTIwIOVA/iPQ0SxnyP3yZR87c/eJ9RQBiUU+RGjYq4INMoA0vDl5Pp+v6feWlsl1cQTpJHA6bxIwOQpXvmvQZ/iHNp+sSG80fVIbi2VI40uNRlWYsjO226yo89SXI2sAQoCg9c8j4B1K20zW5nu5zaie0nto7tQSbaR0KrIMc8Zwcc4J+lek22teBHvJxdT21wyRxxvLfpPeKyrEw2W7uNygSYOWUZB9iCAZ1p8UJdJhitL/AEC5j1CJY4pyl28ACRwyRpsjKnym2yZyOpGcc1wXjPXI/EGsfbYrVrZFgjhAkl82STYoG+R8Dc57nAr0LxNrvg6axuUsotOe4CLMk62ZMxkW5j+UFgAR5XmcHg9CelcF441PT9U1GGbSl2QrFsYfYIbP5txP3IiQeCOTz26AUASfDbUo9K8UR3EsU0gMMqgwTmGRDsJ3KwB54xyCOa0p9a+331/puo6FcRR6hrEeqT2tqpV0jCyExqmB/DJnPGAKyvhxfw6Z4wsby5tzcxwiRxGCAdwjbawyCMg4PII45FerQeL/AAhP4k1rV/tVvHeTruNzfQPNJMpswgWFlUeW4k3biQMg9ccUAefzeKvFPh7xTfaz9nuNMutSidVjngZFEJG1AgIHCDbtx02jrWfpHia0jtNKtNXsnu7ez1GbUZMOP37OiAIR6boxk55DGuo+L2u6Rrlnatp+p211NHdyPHHbCYBYnRMtL5g/1hZQMIduB0ryw0Adr4d8ZQaffahqeo6bLf6xdPK5uBdGNHEikNHLHgh0yc446YzjFZeu6xb6jfabHa2rf2XYQx28FrIcFwPmcsVP3ncsSR68dBV/4ZLoSa6914knsltreJmit7xZDHcSHACtsViAAS3TqBWrZ6h4c0ptS0u21EvGb1vsmox6XFIViJXa4lciVGAGcKOCMjrQBn/EG/kni0mwbQL/AEWKyjk8lNQkeWVkZgQoZlU+WuMKOcZPPNFWPijqltez2NtpmqWuoabbNMYCjzyT/OwLPM8qrl2wDheBjHuSgDpvAs8aeE7BWJyA/b/bavNvGjB/FOpMvQy/0Fdt4PuI08OWatnIDdv9o1wnitg/iK/Zehk/pQBk0UUUAFFFFABRRRQAUUUUAFSRFN6+bu2bhu29cd8e9MAq3YwB23y52Dpj1oA09Ui059VuG0OO7TTiR5IuSPMAwM5xx1zTY2ETYkk3Ads4P5Gq77SCMEYPUHGaaIpJJAWXd6nvQBetLhnkGB1IJHf610VvPI6EmYMoXG5QCR+Fcmv3kC844IJ4NPDusjbX2sKAO+0yCSWIfZWDNJ94quMfWrtyklvALcomXB/efxKc+3auF0/UrmBvOSXaQOVfo3tWzb+LZGmWS+tY3yNvHHNAGpayNNORG3mAZDB1GB9R/Wo9Ulm3FGWFmAB4OBn2xxmo7e9t5ZTJbOIm2/MAclvWlW3aR/Nwzp0Bx09z70AUPOctt+070UDKBuPpmrEV1vVSfMyegBJXb9K1I9HWWIh0UKQSjbfmx68VWfTTD5rxuvy4KsTwenbtQBBLfs6EkmEbSoCk4PPeoJrja6YZjG4yCx+6ali08qY2Ej8scgjOQetVp7GR7rypHMiL0A44FACYebo/CDIw3X8TRbeQGJncoxHG48/zqzFG0amFZVVSP7oBHsDTJVjdjJs37WALlQR09u9AE8wuIgMop4BTaMscetQxsXJE5Eu8HHbH454p81zGsIU+YzkcmUdPpiqqsVy0YwNvJPPH40AOnfZKjbIogBkoo/Td3qpNEvm7zI7ApllAyeeAKhubrJUvKuQM9OW+tUheHDB+it8pI70AWkikSTKlCMYJxjHv/SpLi3Vn3MnyN/Eemfb0rNN2gkUsyHPLbRnHNa63dtcRBIyVLjDZ6YoAqC2VEUxMuByQWyfoMU4lY0ZhHvUjgbsMD9Kv/YgsIKlQsnO0qBmq13bhJPL28jqMYoAzXQGMPEAhJ2g9zUCwlhld5HTgf5xVi7i2/vM52n7gz0qOJZ3tgEQhBycUASvFHFCrGeMhjjbnO2oI4JL2fc8iKqAfM3H5VZ+yb44lZGYuRgHjFRTo0ETI+Nu75FXnBoAsajaaT/YMiRi7fWFmGxgy+V5WPmyOu7NcrW9bgb0KqRt4Cn+dUtWtdj+cmNrH5sdjQBm0V0Pga0t7zXVivNOF9b+WS4d5ESEZGZXMYLbV6nFexWXhbwALm9h1Pw9djyILNoTYXU1yLqWdWbZCQfnHy5U8ZAbPSgD58or6QTwx8JJI7qaPT9Se1tYEnluRJN5ShwCi7s/fYttC9cg9OtTXHgb4bP4Yttc0/T5pLSS7jtn8y6lDIS+11IB+8Prj3xQB8+eGmK6/pwHR7iND7gsAR+IJFZrdTivprR/Cvwuk0a88RWWnakltpXlzyGV5lcAqrowUn5gQQR6/Sq8HhL4V3F7BaR6RrH2qQyB4mM6tbhCu9pQTlFAdWyf4SD7UAfNlFfR8fhn4TSWhnTTNXLl1VLcef50qspdZUTOTGUVm3einvxTIPDnwmmsLm9TStWFpAsZaVnlCs8ioyRq27BchwduexzgCgD5zor6M/wCEe+EJjkkjs9Qljjsvt0jpLKRGmSu0/N97cCMdMjrXkXxT03SdK8WyQeH7ea3017eCaKOYkuN8YY5yT3Prj0oA5CiiigDv/DVyiaHaqQ2QG6f7xrkfELB9au2HQvW5otysemQKVJwD/M1z2rsH1O4YDALUAU6KKKACiiigAooooAKK3PC/hy88R3UltYRSNII2ZWCkqWAyFJ7Z/wA+tZE0MkEzxTRtHIjFWRhgqR1BFAFjTnQSSLJBHKrxlMuT+7z/ABjBHI7ZyOelbUsUbW8YiBWPG3OM8/41R0+1XCgkZb+IHNbVpBKyyKvluuARj1oAhW2DQrGY979SV4IHbmmJF5cki7ADn755Nbtlp/2m3fYGDg4BQ8Z9DV/S9Ee9ZPs6PcTgbTFsOB+NAHIG2kkLLliV5TI6+9Mt9LvLiQt5DlW46YFesJ4KvFuIYblYYRx8uQxIPbI4z9a1JNFubK2KabdpL5WY/wB7GA6N747HnkZoA8gOh3sMm11CbuB3NSt4bkC8ybeAeCWANdJq8FykoUzlJ4yQV3YJJ+n+RVKS4kidDidJycFsk4H9aAM1PCl/saS1uIJBkHGdv86sadf6roU/+lWhlhwVPmgt+RFWV1qeFCABKq9AyjI47EdKH1jzZ1Er/uwBuUnII/pQBd0/xHYO2G862LNvyCdh+uK1IL631C6nAkt2duAXH6fX61ylxZWl/KxtdoZOehAb6HpWJNBLBcSJKJkPOM9DQB6C9raS2uYbhPN5BDyLgn/CsSbU0tRJE84kxwEUjn39xXIPM8akISeMYJxVeGT5wGy2eMA8UAdjYTPqJZo0TBBAXIH5elJDf32kyYSKF0JwUeMEdc4wf51OAYNMikgRmUcHkcf4Vb1a9RLWITqrTbQxYjcDx04oAzYr+O5mBkic7m3SF1+X6AdqtSXlokeyK2bkYOOhJPp3FZ41x5kERt0Xn/lku0CtG31GBF8qUIsmOSFGVHtxzQBmzotxKpjtBHIxxjn0qtdWCxBRvGScjaAw5+netC91q2WTZZlpD3zzn9Ky73UbyaLdFFHEgJz0Xn6UAZ0lv5MjkMhI4CsOg9TUZhnWMsr4Dckj1qOG1nmdjI+Dn5mJzWiLFY1UGdiSMADNAFGLUJrOYvHMWPv29q3LfVIbkMJnRWb72VySAKmttAt7iHdLGQ+MDLcn1OO1VJvD8odZbV3kXGMKMCgCw8M5tw/lDyM9WXAI9agJ2DdhYnPyjOSCK0tNuJo0SC6tmIbgDoD+FQ6tZt52F2BmAGAc7TjmgDLW5S3dtoaUZOWPv/Ko2SW4lAjKqCeAOdtWXtjAQsgZQi8g8Z+g71Krshznao4+oHtQBUjsHWb727HU4p0SxwzL5ttHPEDjy5Nyq498EH34NXIGlZmZSfLxlie9Ry7XRmL8tznPQelAFLwlqFr4Y8SC61SK/liWNghsLo20qsejK4+hyK9Af4m+DTbLDH4Z1iAJDBDG8OpbXj8nPlurYyHAZhu9GIrzq/iimsyhUmXOUf09R+Nc6wIJB4IoA9uh+K3g6DSr/TYvCV8LG9SJJYvtikDy1CoVO3IYYBz6805fi54XHh2LRW8O6s9lHMtwC1+pcurbgS2317V4dRQB7Td/FLQJvDOraJpOg39u2qQQ2pkmu1kCiNEiQ42joqD8ea0Lb4p+FdA1e58nw1qctwguLWaSe/EhnDuu8uWUlj+7QDPQDFeDgkdM1qeKB/xUF/x/y1NAHf6x8Q/D39htaaB4fvba9MyOl3dX7yPCiqyCNGUqwUKxULnGCQc5zWnYfE7wlaeFn0J/Dmpz20jRyPI94gfzUREWRcL8pxGp/P1rxiigD2f/AIWb4R3Wrnw9rZe1tZLSJv7TGUV87m+794hiM9Oelea+MtU0/VtYE2jWU1lp8cMcMUEsvmMoVQCS3fJyfxrCooAKKKKANuwuRHZxrtJxnv71l3z77uVsYyadFc+XGF25x71DK++QtjGaAGUUUUAFFFFABRRSgZoAlhuJYG3QyPG3qjFT+laMEsk9vtnCtIZjKHKZlYkAcseSOOnrmqVjatcS4x8i8sfaugDJIwib5mUYXAGRjtQA22gZZcrjPU8fzrr7PR7ebRpJXmEb4IGeMnsRWDbxeWQZiFOMfODg10nhqUecEvYC9tglQCFP4f8A16AJNJsRCEWWb93IRwp+Y/nXoWlrbJYmOJ5IpVOAzfKVx1APr/nmua02W0aRA8LlOUPB79vaulguTLY7o3Rm2lSJ3CnA/hbv0oAtXccElilxY37tKXzkZbAXBPTv3Gai+yqupROkzb/KMqtuK+YfTnoeelXbWSB0Z3YzkYXy4lGYsDk7uPyNVdIjt7zVGbUmeWzO4AMMknpj/wDVigDznxXdLc6q8s4diM53oFcfgDz9a5l8Xm1Fmfep+VSemetd74z0q1S6aGzzJtXesZcA4J6c81xNy0RyuM+oHDL7ZoAqLFPbsfOjw2SQSMZFTWlmswa4ZJJRGcsE6AY+lNWOB5QWJKbSDhslav2AkiLopYK/ygnIOPegCAJHCQIVZpBwd/G0ex9avRx2mrpLbXbPHcqMQuEHJ+v4VKs0hVxdRBipwuFwD/hn1p9hZJP5m1JI50behzlf8aAOMvtLaCUxtIWLcgsMZ/CprHwvqtyrPYW4n2IWJQjIFd7qdtBqOmiOaEJNHlY2HAPrmsfwzp9nbFlm1+XTphuGxWK/z/KgDnrbUrmwBivLbIz0OQB2qSDxSQksJjRYW/hAHy1V8SQeXKwiuvtIY8MW6+9YkaMpAbaARnJNAG3datEYytjbrGB1JI5FZrzzZ2uFVxzn1B/lTLO1lmcKikE/jXSaRocMkqC+byo+5Ayx+lAGDp1u81wq5ba3B2+n9a6K50SAwK4mLSKMsHHT0HtWulvCi/6AixpGAvzR5ZvXJ/wrSFhNbBDqFrK6zYIAXBCjvz/I0Aclp2gi5lZJ7yK1kClsSccewGaYYo9PuFC4lcH5X2nFdrqVu0UZL2VwoBJjeaPaWHoMVQXQLvWoJpRCIkjKjk7Qu7oOfWgCLyprq2jkht52tjy0gTp9PQmpLKWWwuUS8ibaAoUHkDHPTp6daS10vxHprtFBbvLBj5lIJTHrmtC2CpA6X0scTn5iqqzO57j8KANHV7W01y2a8vrtY7gEL5aIBhQPbgVyxaB5dsXnNOBt+bGFGKfHbzQ3E05tzIN+DkZHtxUF9Z3Dy5ZXVsA7Yxjr9KAMu5iMYwwczHjczc/Sq00DqwaVzkDIVsit97SRkjm+ztEjDaN4OWb1BqtJChmcNll9yef8+tAGTJM/2YRBDhsnHYfSkiAt0w+wtjrjt9KsXK7SW3P/AHRleMe1VYrWV2G1gNzcgsOR70AVLklQwwzc4xnGKzNXElzK106Qo5ChliTaMAAZwO5xz6nJrqb+zSKJZN6bFPTOAv8AjWOyPOSIN0xY84Xr+FAHNUVb1G1a0nKN9centVSgBQcVp+JH8zVXlIAaaOKZsdAXjVjj2yTWXWnr4JubaQfcktICp9cRqp/VTQBmUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU+NS7hVGSeAKfa2011KIraJ5pSCQiKWJABJOB6AE/hW3omnMI/tDfKzLlMjjH1oA0Yw14JHuJGe4kILuVC7jgDoOOgpsVjK8qvEhKj5WYHrVhSXcAoEbpyOD71agWS3mAiKh2G0j1/8Ar0Aa2jaU99PEVZdqnnI4z6V2utRLZ6TGsyKXToVUMD6Z7isvw3qOnm3S11RGWUHmRQQ6f4j61r61Bp1xCYI9QeZODEzJyfY0Acnbamk0hFypibOCwJH41pRXRgGTdLLIwxHIjfMPqPpWPqGjBQwiwzYweo6VDYSSWqA/ZxIvQuD8y0Adr/a2dLZopMTZxkZBfjnHStfRtWW1tA/mZkPAjAyyn6VwkeoeZIFuGMqfdxt5B7HjGa2NJ1ER3UkDQxMxGNpJUH3/AEoAm8TvPrF6puVjDp03jaSPyyDXH6pZrFLny9q4HzBt6mt7XdUZJMSDzFPIG48fnXNzq0igsG+Ylup4HrQBEyLNIx2pEqqcEDGfenRzbNo3FwerAhs/j/SnWs7iULBsAPygucg/hV6SxXT5gYBvd/vx4HBPtnmgAjkhFr/rWMrZBDDj6CtrQTNAskkcUMi4+dRKFI4xxniuTu0lN68IkCMmGLKM4qQXk0B82aaK7g6DbJtPHtQBt6lLE94X8q6tZhgsrfcc9v8A9dRXXiC3srZg2j2F2HA3bx8yH61Sl1BpYiIZcRORlX5Az6VYhtLGG180l548lXAyu3j8RQBwuqX0d5KAtsIlHAwTgVFa26zKSn3+4x/Oty/0G3eF7mCdNpz8h6r+ZrOgRbWVsgEDvn9KAOp8GRQyQTvKocopIVxyT6j0rprLTla2N5eLHlNqrG8hy2T6DGAPeqvgwlIT5FsNpQ7jwQB6102syyRWUMaNFDx+6Z+j4HJJx0z/AEoAz7sxyRyNawx2CJtGYjgBvXnnmrOgb78hJYJJEjmwJwh/NjnBFZVjMcTcBgRh3Qhix+noa63QNebRbS3GoW0aoqZjQqEB54JGMn/61AGP4gvZJ9Vlt41RoUXA2twR/sZPXjtVzTNW81pIWvIo1wCQ8SlpeORnrkY61z+q6g+taw7ea8seWxtbYee30+lY5tJ7J3Lq8B5JJOcA9B9aAPQbzSi8EP2Se5ZS+58OOn930/Kqcdnp2lTO1wNwwAFL56n7wK9BXDWt/cOzRJPJs689GP0PrUd7e7IpVe1jZBnG/IBPrigDttc1TTroeTZDzGViWflfYAew9KsWEfhoIjXN1502zASM/Iv4jqa8uhls47RzcGeW4ddwUHaF9Tn0qra6gbaTzIpNyj+Atwo+lAHrWsaPp1wkZgEqwlCUb7wB9z2rz/UoJLKUfKp25AcDt/WrOjeKPsjje0jROclCMrn1xW1q80euWzTx2wRFPysRyx9/8BQBxLuQ5Lkl+u0jOfr6UizlBiJQFX727uewFTTwrHM2FG9TjhjjP06mo4jsWRSgDjkuev8AhQBTktnurglk8lWG75+v5U502KVtFMSkDc27JzQwaeT55AqkgHqSR70XVo1vk7x8vA4xn6f/AF6AM7UEeWzNkofyTJ5nOM78Y3E/Q1ysqNHIyOMMpwa7WMLJA/muFwc/WsLUbOW7mdrSN5WRGdgiEnYoyzcdgOc0AYlauuf6vTP+vNP/AEJqyq1tVbdpejseWNuwJPoJXxQBk0UUUAFFFFABRRRQAUUUUAFFFFABRRWqmh3raGur7E+wNcfZd+8ZD4z93rjHfFAEGkx7rqN3yI1POO/tXVieEviNW5B4zwD7ViwwRxIF3lcfdYchvep7fJuAS24+g70AbBZdimPcMdGxwPatHTlREMj70YDkMoI+tVNPP2gKHIjUfLz0NaTSR2+WhL/LyNvIH+IoA0LK1+2TI0bFWbo55J/+tVq2vrq1lkVpBMgG0ZA4HqDWN/a0cMnmIg2kgkJyPy7VuxXttdLCUiVfMO11z09/rQBZspkv7pAG+VTlfMYZPtmpb22sCjC9jmtHd8bo0BU+5A/oagbQLp2mktIXmiUbm2nOKyGvJo1MIeYW5PKuMY9RigC/PZDTzukiSSzb5kcDr9O4qnHJbzSiIQN5u4srhuQPQ1tWutRjT44gfLlj4i+ckP6/Q0xvLnto5bgQtKXKs3HH1/xoAzCrXKIl5OkkakbIy2SOfTrUtzoSzpGLdt+4AqcgDd69qr3byWokWVY2DAhHXhvzFYv9r3aMrW0xKRc/j9DQBbksVtpyt3GiyxNtYMDg+9SsqgfuAWduQFFa8M097bpqFxBFMgXExYhjn3X1rOa3nS73wFAByo3cjPagBtrbRzFtlzClwFJfMm1j9M9aoanouEDxqoPUsCOffFSatY3V6wd2VSOiMMkfQ1Rsra5WcxTybAOCC3H4UAVLG3eG6ASRRtPOeg/Oti4kuBdKy4d8YLIwCkehrQn0u2vI1Eas0nfykIH4024065t4IYrkMyZ4TgZFAGHLGHBYo4Vsk7mBHH0FZTsRNtQlQRjJHSunFtAkkiyxhFX5V2s2T7Vh6lDJaSDGXVz8rEcr6AmgDoPCtwtoeQ4V1IznINXp2s7y1lln1KMSo3EZX52X09M1iaNLvKKI90pUgKWxn3FaFhodrLO0d4fJO0k7eSSfWgDR0i5sVXyInCRtmQO/zMOPal13VZp7VVa4kZVUGLbjtweO/wBasHw7FpliZbeVJEYgbQnOPU5xisbV4VtVwXYM6jChOi/WgCjpmoXFrcC4RchDv+cA4+lal7qR1O6MoNy5kwSXC5/KuQaSSe5KoCy9812vhHQ7+/lBgaP5Q33uApxwMUAJpE6rqLtFbxSE8KZFxnH14qvr08c1zIr+UMdY0BwCe1T6rpJ0hfMeffdZ3MA23GewGaxNqbnmkbd1IYHigDK1K3BkYwb2QYBJ4GfTNZ8cax5CKXbqSTxmulvLiMxmNFZ4/vAA5Cn3rn7p8xOfM244CjvQAkMyox2kb267ucVvabf3EO1fOKoOAOpJ9q5lTthUKdpI5zxViCZYnADHP+yM0AdTfSCJfM28vzjaGY+/1rGnVhNvCMg9GOKu6ZdrOrJOCNvRyuQfaq1/On7yMQqsqkc45oAiL/ZmQyJG+fmHXJNWJmE8cc0mJLg5OwrhVH9ahkfyWTMwZzySwzz/AJ7Uyd5JUYPu2rhmY+vtQBXu/LVgZPmOMjaMAVky/M+EDYIOTnkj0+lajx7pSUckkcsOMCqVyEgGMb89+9AHP3Ue18qPlPb0q7qn/IL0b/rg/wD6NeklXeSi7SD19q0vGOjXmhJpdjqKIlxHbsWCOHHMjEcg46EUAc1RRRQAUUUUAFFFFABRRRQAUUUoGTQAVp2kDrGTzuxu69KiFqLeeLdLBICiyfI24DIzg+hHcdqt79pLJ07EcigBm4Ko/hOc47Vcsw7FWCk4547e1RwzZHKjfnofSrNpKplyPlOfyoA0bOWRIj5Wwbj86OOG9wPWrdtcSx7gkuPRH/xqiJzJxvGVPKv2P1qKWXc20FdrZ6jkGgC952XZlOzceCv9RV7T7iPzH3qCzf8ALQ5xn2rnCSF3OST0yOtXoL11jXb8uMe4P1oA7Wz1eWGaMRLJ5gIVCpPX1INbcuo2mpNGt7aIJQw8ydT82O/tXJaFqMRuo/OKIh6lhlc13ulRW0quss0apIm2No03jb9PY0AYE1hp0M7i0keS0LcHf8w7gkYp9xDHFaFLaVJ5yMupG4fUHt+NbWp+FpkhWTTJoroH5fLU7XP4HBNZF/oeoW7iNhcKQu5ww6exoAzBpU0lkGTcIsZzxgn2rlZLQJcupLgdMgcH2r0HRZmSN0lcGOYbZFX5dv0zmrX2O3nnmbT9OMxUDDMPlbHXPP8AKgDmNN0mS1VJJUZo2bkxtkkV0sEFhczLFCsohVcq8xwc9+e3tmrOn6dcTss3lbRH8jxqM4J6HHpW0fDbyXaosyp5qkKQjcH0wRigDIudBkm04y2d3tP3Wjndc59vUVzd/wCGdYCNNHFHKclQRt/Ou3m0GSG4Mb3ARFGBI38TDtgUhsldm3xuUZclyflQj09KAOM0zTrm3VTOsivnqhPB/Cm+TKjvNfQv5Q6bnPP410eqm3tUZoHZ1RMF8mNlPr7iuS8pZowTqapGT1fJBPt6UAVNQ1K3BEcMUnTnzG/qKzZI3adJJmQhm+UEE/8A16sta2qXEjyO88aDmTPU+nNUruUTSr5GHCnkNwF/GgDY0rS5k33ihEjjY56Z/LtVPVNQnR0KBwQTk7altFunDKI4wSOgJyPfAqtfQBHYSlmY5xjK4/z6UAWrXXdQuzHA53RKN+MEnP19Kkuba6v7ae9u/MkhXuPlyfToasaFcQQ7AtvIZSMMY5AMj3rV1bUoYLTyBY5hzuVJn6Z6k4OSaAODs3MN2u9Nig8BhxmvQvDVzC8UhadtoG9gBhT/APW/nXnGp38nmsY402k8d8UW2qvbJzNNhuMA5oA6/UZvPkkuN7Fz1zgdf7uOlVYVW4gKRICynOGyqqPr3NYVtdy3QZSH8oDJxjJHv/8AWrTs7lRaeSd5BOfYn0JoAqyskay4jVAM5Zun/ARXPXMR3sY1bDdzW1e2xeaRmKqf4c/dH41lTyBk2ncFU4GTwTQBXWMsRkAY65PFT4S3XeZELdcEVVJypxkAdRViMQO4D/vHI47UAS2eoTxzB1I5OMkcj6VZn3svmsQS/Hz9/pWbLAyknCqucjnBP4U83kJjKD5Txksf5UAWZpcSYR/MlHLfLwv0NVWmYs37xirfKadKQYgCxRW7A5JpoKrMgkBRVGcsRx/9egC2F/dKwLtxggHnHv6VmXe1n2kqAvcH9KvvcqEK23mKp445BqmwQKCy/wAWcseKAMx0GTkEgdPerF+C/h+wyct9ouOf+AxU2c5cY428knjA9qs3AH/CP2HXBnuMe/EVAHPUlW57QpbR3HmRESMy+WHy64xyw7A549cGqlABRRRQAUUUUAFFFFABTkG5gKmso4JbhVu5nghOd0iJvI4OPlyM84HWmJjA7etAFmIhSQT8o7EVdtlWQEFgpbpmqkAVsAgE+1XUYRRg4yp9/u0AI6MjAsdpHAbsasW4jOQSGJ98YqOM+a4CkMOuDyDTljaMlnHynuBxQBNIg8xSqESDrlshhT0kMeN0R2k8gdah3kpyrbgeD6inxhR84JXnOCeRQBYjdH3Agr9c8fWhYJV4WPg9R2P0NMjHmMxZyc9/WrdufL2sOBjBAOd1AESsUMaMhUdcA1taXrF9YeXJbyOAGyMHp9arwRCcAgnJPyrt5FbFpYq8JcLGIwMFyQDn0oA6vT/GlxLbK8lpEJhy0qRgZ+q9M+4Fbdt4piuLxTbZuUcAul2Dtz6AdsVwER+yMWjf92FAZSuOfxqzpmJmM9vdwrKG4jZ9h+gHQ0AelHX7aKVZv7Mhs1dskkZQn2471ZtfE2m2Vu7pbRfPw0W0KHBPPPT868+vLmOVY/MuLplU48sJs5/oao6pepbj9xNOE4OwkH9eaAPQbrXInlljtpVgt5QTtidcLj3qjD4p865jDRl47U7jufbnjB79a81j1FDHIyuWLcYXHFXWjn2wFl3g8k7y36UAeg23iFprlZnjVoiwVU24Kn8ulaEt+l46fYpkXy2IMbIeffI615a11PDIVjkOTwACentWuNWbyQs7sTjgx/Lg+9AHSeI7rUbnTmhZPtUZBUngsD9M15re6RcwATHeI2OAMZz+Xet+HVJYoQZE8txkxuBhse/rVAztqKsTIevoNx+me9AHKah9pUSLKAi4BVcHOKfoyTPOFjhllJ9GwPrXZTaQBZMks9vGFXgl1Dc+uDXKQlLO+kEgEuD0BxkUAda9lfrAhW3ZSgzuJ4H45rG1e8J8llSNXzyWHH41Zg1MswaBYYvLGRvYnn8ax9aupTCJHRGZmyducUASaZBLc3LcpvU49BirWtWwU+SZC2VydijafxrAtbp0lDIqls5wOua09butSuLQSScQAAcgbv8A69AGDdyMqqI8bckZbpn1qkkjIxUoG7560juzlmLBiOCccUxH+b5W4POM9KANOyeQuQA3zDsO1bFurqyK+91xllzux+Vc9HKUlJydnvwMVr2sTzRIuZQDndtUgY+tAFmaWeaXbhVUD5FUE1lXsTGbGBI54Pp+ArRuI4LWENHMpOMfLnj61lTR4CyQAFueSDkE0AVpmMbhcqCDjJHSkDKpGHZs84HX8TVWRw2QxLYPzZ7/AI1ECzEgE4PYGgC6ZUwzK3PTA5qvuTORtODjBHJp0dvmMnLbc5zjioNgJwpzjvQBeiK7v3jYOOFzmleMrGc4CZ4GMk1XttiHaQzk9wdoH41NNKWG7G0L2Xn8c0ASQTKEIKPn+ECjyXmlRRHl+uC2agWQYG5ny3o2Of61N5kkszeVlWAx160ARzWxRZPMYMc4Az+ppdQONAsdrHi4nGR0PyxVFc7ivzls8Ak8UahkaHYBAAPtFxwOn3YqAMpzgdiTxUDDB6VMVcsB6c8VLDFCwkN3I0K+WzR7U3bmA4XqMAnv29KAKVFKRg0lABRRRQAUUUUAFKODSUUAXrO5jjkRnBUjuOhrZVftJLRKrgjoxGfwrmKs2d5NaPuibjuDyDQBrC0b5Sf3TE8YOPwpZAywnzGZtp5qSw1WCclbg+Wzdc8qT6+1XJokmiVXBU9Q+MqaAM6OTaAqNlCO5walifJCykkDsR1pXtHRsDGT36riiOGQAgAdPuk8H6UATRkmRggIC9u+K0bXcmGePC/3gM5rKkjcbXRjlh2HSrkVzKqLGCPy4NAF5YpF2OhRhnJAJ/XmtSO5ngh2Nbr5RPzblwD+PrUWmxpgSvN8zdUwDmuo0q2F2jo0qKmNx3KSGH0oA51rtZUKGQwPn5QeRTreynkjZwF80DAAYAn3A712H9if6SCkdu6DAZShK/n2p88emJILWW2ktXz1Yb0PuD1oA45VCt/p8rlweMMeSO2Ko308dwDsWRee5J/OuwvvDokhe4sLi3k5x8uUA/OuTvtPuoWIkiMTdMgg/lQBHGFmKpCqO+OCTtwat6Xd3UV4v7lpiODtx196gs0C3IJ+aTptA5rVgshGszxuBIRwZOn4EUAUbuZ5XCrGMmQkHGOfYU+6ZGQCXhj/AHAc/rUjWrXAEkxKBTxlsg/pVHVEe2IQKpZumxjk/h6UARWs0gumjVjgZHJHJ7CrP2mZC0rtFhTjaBg/TANVI3KOUiAXOMt1AP8AjSsZNrNjzpM7cheD+PrQAaldxyWvHljJ+9Eu0/rXP+Z853SDap5crk1bvZjJDsckZPKlMY+nr9ayoYQJGJyI93RjjNAHQxywtEq/6w4zvIxj8O9VZ/3n7tSr55IbqP8ACooGjiTcZ1JHTBz+lMljZsO+0p1NAFOdxG+MMHz2bmoZpnYAszOB03ZpZZER5Ao6jAYiq6ttchyRnsaAEaXCYByB1yaEm2sM4A9SahYrn5QOOuO9TwQvPJtUjjkY6UAXI5wVyhVSOgz39a0LGUMv7x3Zs9cmqcViytvud5HomOfwqVlWGcGMEL1waANnykaEqqgSNn53YDaPeqBV0R0eRNuOqtwael46wskSNtPXI6fWsuRXf7i5lJ5wMCgCrckqChVcg5471ZtbbcmWVVB65zk/lUkFnJNL5bffYgKF6iuxsPDUv2Vri8ljjhVTghiTkdh6mgDjZoyG2xNiMDgNxms64Jj3bsKOgI7109/ZRQPsjJdG5LyZ61iajsaTJIJHTjAA9qAKFu5DcE57Z6VYW4cBkByWOeOc1WkZS/ZQe+OtNE7I2I8L64oAttCVV3dhgdSeM1E8jJtMe0Z5LAmoJ5C4AOc9etBWRU3ScKfWgCSR5HJDtuBOS2eTWjcjy/D9g2QuJp++e0VYzzKANuTjt6VcvpWk8PaeWP8Ay83HHYfLFQBTkuhx5aAcYyeTVYkk5J5pKKACiiigAooooAKKKKACiiigAooooAKuWeo3FocRvmM9UblTVOigDoLfVYZHVGzECMEHkfnW1I0TQLkI3PVGBrhamt7iW3bdE5U/pQB2EiR4VUJMZOeeRn2oWJ0mxKOAP4lxmsC21chj56BgfT/CtiK/iupFCyDjGCpwfyoA1IWiaHDcEHnjj8639EuwjBUlkCg8gng+3HasCGN2cElgv+zjn8KuiCUL+7UjLcgZXH4UAdnCWYM1tKzOOGBlyMe2a0nvfLh/0lnnG3/lmynj0wR/KuCiu5IZjGu1MjJDkH8jVuHUJrS4SSTYY052t0oA1NTRRDvsRKFJ+bL4bHoQOKwZpJ4iCcrkHBYj5qt6zqqXskLRx+TKV5wOg/ma565ZdxCH5sbtu48560AbNnPA0TvKFRz1Gzp7jFa+ntAlo0okyyj5RHnBHrgiuKNw6pyqndxw3IqxDrDW8Bi3AP0II4+tAHZTH5I2jiNyo+fbuC4P41mXzASIZYQrA8lmBIz0x6Vm6fr8sCMRJCcjqyjGfSo5Nbklc+ZBAVOBkLx9RQBr28VnLCySbTKxyCeo/Cq89gTKyoc7FyAv3T+VZZvTK8azMojU4AAAJp01xGJSkTuGx3Ucj60AU9RtAykbXjKc8jlh+NY0pI2jaWHYk/drf1Odxb7BAh46kEnHuayrOWPzWZhGc++4UAV7K1mdtoxtb+7yaku7Z125m2445BzXQ2GoQsNojDHH3o2Cj9ahu5iMiPBc/RsD60Ac0bS4ckIA+O+3mq1xC0coEgyf9oc1bub6XzCWm74wOBVKWdpHDYTCnPOeaAK7rmXBAGetXdJlRJgjBNuepXJqnIxaUnOCfbFPiV1kBU4I54oA7yyspbq2P2U+Z6lgAazb/Sp0hlfG4IcHJwAf61FpOpzJhFZg46leAfrXYWMpvE2ssCx+rD5ifpQBx9lpl3cIwL7UGAxycCt3TfDMjzFHB8sgYZm5I9gK6CKzRv3cUgjDcFMk5+oFX1uhp5ARZI9pCmRvlAHp9KAIrXw7ZaJFJcXwKyN9xSBnPqcnp+FV9a8RWjWaW1t8zRr97b8o/D1/CsjWtQhleU3UryqfTjH09a4u/wBTjX5LeAAddxY0ARa1fPMwUbyM5LYxWOWKAgkAnnnrRPKZcsckk9B0qszgE9KADIz1AoDAEZOBUbPnpxmm0AWROI2JjGT6moZZnlbdIxJ96jooAK07r/kXNP8A+vm4/wDQYqzK1Lr/AJFzT/8Ar5uP/QYqAMuiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKUHHTrSUUAaWn61fWMgaGXIH8LjcK6aHxwZ4wl7AUIIIeHnp6g/41w9FAHfvrVnexZWdN4OfnO0n/P1p1rOlv8AP/A44Ibd+lefVLFNJEcxyOh/2TigDrrm9O8uQxZDxk5Wqk1y0jFiuF746ZrFGpXH8T7vqOtCX58zfIpYnqM8GgDTknkA27m2f3T1H0pxudoUqS3HVl5/Ks9LyMnkkZPRugprSRGQ4lyvrzigDSOoNnGxMDuBikmmLkMsgz2UDb+dU1YBCFdWJqLOW+cAY7jrQBqxXzAFXKkegOalW6KOrqNij1P9axxMA52p8p6kU8yDB3PuA6AmgDSmvZJ1cCRig/vMTUVskZILvGzMcgjms13JAB5I6Z6/nVjT0Vmw4YDqcEUAdFYeVvJBjG3s2QB+VRXNwkUrsZYWGMAHJA+gqDyIFGUR/c76iureyEWQrb/RnAP6UAZc8pLOI2UhuuV4/WoRuiwcjB4ODU1xhGU7dg9M5qtI0eflDY780AL5gzlvmHqRmmiXHK5z046VASB2oDKOoH4UAaNlclSGDKm3/ZzW/bakxYSmcbU4GRjNccZPSnichcKMfU0Aej2vjB0hMSoqhT1jGN319qoXniWeZeHTPJwOg/OuEErDODjNNZi3U5oA2b7VWkclmLHtz0rPuL1pcZVRjpVSigB7yMx5P5UyiigAooooAKKKKACtXUTs0bSY1Hysksp/3jIVJ/JF/KsqtTVP+QXo3/XB/wD0a9AGXRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAC0lFFAC0odgMZOKbRQA/zH/vGk3t602igB/mv/ep6XMqDCsMH1ANQ0UAWWvZyANyjHooFSNqd2yBDNgeygVSooAe8rv95iabuOMZNJRQAuaKSigAooooAKKKKACiiigAooooAKKKKACiiigAq1c3JntbSIqALdGQEd8sW5/OqtFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this longitudinal image, there is a very echogenic portion of fetal bowel seen in the mid abdomen that is as echodense as fetal bone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Chasen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16784=[""].join("\n");
var outline_f16_25_16784=null;
var title_f16_25_16785="Endometrial cryoablation";
var content_f16_25_16785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endometrial cryoablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cryoprobe is first placed at the fundus, angled toward 1 cornu. Probe placement is visualized on ultrasound. When the freeze is initiated, the progress of the iceball is monitored by ultrasound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Levy, BS. Her Option Cryoablation Therapy System: Using Ultrasound Guidance. OBG Management 2005. Copyright &copy; 2005 Dowden Health Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16785=[""].join("\n");
var outline_f16_25_16785=null;
var title_f16_25_16786="Patient information: Sleep apnea (The Basics)";
var content_f16_25_16786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16178\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/56/15237\">",
"         Airway in a person with sleep apnea",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/30/40419\">",
"          Continuous positive airway pressure (CPAP) for sleep apnea",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/4/38978\">",
"         Patient information: Daytime sleepiness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/58/22434\">",
"         Patient information: Insomnia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/5/35921\">",
"         Patient information: What is a sleep study? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/25/26003\">",
"         Patient information: Sleep apnea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sleep apnea (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sleep-apnea-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H17011366\">",
"      <span class=\"h1\">",
"       What is sleep apnea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sleep apnea is a condition that makes you stop breathing for short periods while you are asleep. There are 2 types of sleep apnea. One is called &ldquo;obstructive sleep apnea,&rdquo; and the other is called &ldquo;central sleep apnea.&rdquo;",
"     </p>",
"     <p>",
"      In obstructive sleep apnea, you stop breathing because your throat narrows or closes (",
"      <a class=\"graphic graphic_figure graphicRef75747 \" href=\"UTD.htm?14/56/15237\">",
"       figure 1",
"      </a>",
"      ). In central sleep apnea, you stop breathing because your brain does not send the right signals to your muscles to make you breathe. When people talk about sleep apnea, they are usually referring to obstructive sleep apnea, which is what this article is about. &nbsp;",
"     </p>",
"     <p>",
"      People with sleep apnea do not know that they stop breathing when they are asleep. But they do sometimes wake up startled or gasping for breath. They also often hear from loved ones that they snore.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17011482\">",
"      <span class=\"h1\">",
"       What are the symptoms of sleep apnea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptoms of sleep apnea are loud snoring, tiredness, and daytime sleepiness. Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Restless sleep",
"       </li>",
"       <li>",
"        Waking up choking or gasping",
"       </li>",
"       <li>",
"        Morning headaches, dry mouth, or sore throat",
"       </li>",
"       <li>",
"        Waking up often to urinate",
"       </li>",
"       <li>",
"        Waking up feeling unrested or groggy",
"       </li>",
"       <li>",
"        Trouble thinking clearly or remembering things",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people with sleep apnea don&rsquo;t have symptoms, or they don&rsquo;t know they have them. They might figure that it&rsquo;s normal to be tired or to snore a lot. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17011489\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you think you might have sleep apnea, see your doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17011496\">",
"      <span class=\"h1\">",
"       Is there a test for sleep apnea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have sleep apnea, he or she might send you for a &ldquo;sleep study.&rdquo; Sleep studies can sometimes be done at home, but they are usually done in a sleep lab. For the study, you spend the night in the lab, and you are hooked up to different machines that monitor your heart rate, breathing, and other body functions. The results of the test will tell your doctor or nurse if you have the disorder. &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17011461\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to help my sleep apnea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Here are some things that might help:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stay off your back when sleeping. (This is not always practical, because people cannot control their position while asleep. Plus, it only helps some people.)",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight",
"       </li>",
"       <li>",
"        Avoid alcohol, because it can make sleep apnea worse",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17011527\">",
"      <span class=\"h1\">",
"       How is sleep apnea treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most effective treatment for sleep apnea is a device that keeps your airway open while you sleep. Treatment with this device is called &ldquo;continuous positive airway pressure,&rdquo; or CPAP. People getting CPAP wear a face mask at night that keeps them breathing (",
"      <a class=\"graphic graphic_figure graphicRef65324 \" href=\"UTD.htm?39/30/40419\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      If your doctor or nurse recommends a CPAP machine, try to be patient about using it. The mask might seem uncomfortable to wear at first, and the machine might seem noisy, but using the machine can really pay off. People with sleep apnea who use a CPAP machine feel more rested and generally feel better.",
"     </p>",
"     <p>",
"      There is also another device that you wear in your mouth called an &ldquo;oral appliance&rdquo; or &ldquo;mandibular advancement device.&rdquo; It also helps keep your airway open while you sleep.",
"     </p>",
"     <p>",
"      In rare cases, when nothing else helps, doctors recommend surgery to keep the airway open. Surgery to do this is not often effective, and even when it is, the problem can come back. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17011557\">",
"      <span class=\"h1\">",
"       Is sleep apnea dangerous?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can be. People with sleep apnea do not get good-quality sleep, so they are often tired and not alert. This puts them at risk for car accidents and other types of accidents. Plus, studies show that people with sleep apnea are more likely than others to have high blood pressure, heart attacks, and other serious heart problems. In people with severe sleep apnea, getting treated (for example with a CPAP machine) can help prevent some of these problems. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17011387\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=see_link\">",
"       Patient information: Insomnia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"       Patient information: Daytime sleepiness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/5/35921?source=see_link\">",
"       Patient information: What is a sleep study? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"       Patient information: Sleep apnea in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/25/16786?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16178 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16786=[""].join("\n");
var outline_f16_25_16786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17011366\">",
"      What is sleep apnea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17011482\">",
"      What are the symptoms of sleep apnea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17011489\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17011496\">",
"      Is there a test for sleep apnea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17011461\">",
"      Is there anything I can do on my own to help my sleep apnea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17011527\">",
"      How is sleep apnea treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17011557\">",
"      Is sleep apnea dangerous?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17011387\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16178\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/56/15237\">",
"      Airway in a person with sleep apnea",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/30/40419\">",
"       Continuous positive airway pressure (CPAP) for sleep apnea",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=related_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=related_link\">",
"      Patient information: Insomnia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=related_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/5/35921?source=related_link\">",
"      Patient information: What is a sleep study? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_25_16787="UPJ obstruction";
var content_f16_25_16787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ureteropelvic junction obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Laurence Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16787=[""].join("\n");
var outline_f16_25_16787=null;
var title_f16_25_16788="Calculator: CDC/NCHS infant head circumference for age percentiles (<36 months)";
var content_f16_25_16788=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CDCInfantHeadCircForAge_form\" name=\"CDCInfantHeadCircForAge_form\" onkeydown=\"clrResults();\" onkeyup=\"CDCInfantHeadCircForAge_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: CDC/NCHS infant head circumference for age percentiles (&lt;36 months)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Sex",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Sex_radio\" onclick=\"CDCInfantHeadCircForAge_fx();\" type=\"radio\" value=\"Female\"/>",
"              Female",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Sex_radio\" onclick=\"CDCInfantHeadCircForAge_fx();\" type=\"radio\" value=\"Male\"/>",
"              Male",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"CDCInfantHeadCircForAge_fx(); minMaxCheck();\" onchange=\"CDCInfantHeadCircForAge_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"CDCInfantHeadCircForAge_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mo\">",
"               mo",
"              </option>",
"              <option value=\"12|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Head Circumference",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Head_Circumference_param\" onblur=\"CDCInfantHeadCircForAge_fx(); minMaxCheck();\" onchange=\"CDCInfantHeadCircForAge_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Head_Circumference_unit\" onchange=\"CDCInfantHeadCircForAge_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Z Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Z_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Percentile",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"CDCInfantHeadCircForAge_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option selected=\"selected\">",
"               1",
"              </option>",
"              <option>",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         Head Circumference for Age Percentile Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &lt; 3:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Microcephaly",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;= 3 and &lt; 97:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Normal head circumference",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;= 97:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Macrocephaly",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       Microcephaly is a",
"       <b>",
"        Head Circumference",
"       </b>",
"       greater than two standard deviations below the mean.",
"      </li>",
"      <li>",
"       Macrocephaly is a",
"       <b>",
"        Head Circumference",
"       </b>",
"       greater than two standard deviations above the mean.",
"      </li>",
"      <li>",
"       At the extremes (&gt;97th percentile or &lt;3rd percentile), small differences in percentiles represent clinically important differences in head circumference. At these extremes, the z-score is a more precise reflection of how far the measurement deviates from the mean, and is a useful tool for tracking changes.",
"      </li>",
"     </ul>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Examples",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"3\" class=\"medCalcFontOne\" summary=\"MedCalc 3000 Table\" width=\"40%\">",
"       <tr>",
"        <td align=\"center\" bgcolor=\"#cccccc\">",
"         <b>",
"          Z-score",
"         </b>",
"        </td>",
"        <td align=\"center\" bgcolor=\"#cccccc\">",
"         <b>",
"          Percentile equivalent",
"         </b>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         - 3.0",
"        </td>",
"        <td align=\"center\">",
"         0.3",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         - 2.0",
"        </td>",
"        <td align=\"center\">",
"         2.5",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 2.0",
"        </td>",
"        <td align=\"center\">",
"         97.5",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 3.0",
"        </td>",
"        <td align=\"center\">",
"         99.7",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Percentile conversion from Z-Score is done by table look-up in the standard Normal Table. Percentiles are provided for Z Scores between -3.09 and 3.09.  Values beyond these extremes return percentiles of 0.1 and 99.9 respectively.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        LMS Parameters for Girls: Head Circumference for Age. National health and nutrition survey (NHANES), CDC/National Center for Health Statistics.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        LMS Parameters for Boys: Head Circumference for Age. National health and nutrition survey (NHANES), CDC/National Center for Health Statistics.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16788=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"n = new Array;",
"var L = 0;",
"var M = 0;",
"var S = 0;",
"",
"n[0] = 50;",
"n[1] = 50.399;",
"n[2] = 50.798;",
"n[3] = 51.197;",
"n[4] = 51.595;",
"n[5] = 51.994;",
"n[6] = 52.392;",
"n[7] = 52.79;",
"n[8] = 53.188;",
"n[9] = 53.586;",
"n[10] = 53.983;",
"n[11] = 54.38;",
"n[12] = 54.776;",
"n[13] = 55.172;",
"n[14] = 55.567;",
"n[15] = 55.962;",
"n[16] = 56.356;",
"n[17] = 56.749;",
"n[18] = 57.142;",
"n[19] = 57.535;",
"n[20] = 57.926;",
"n[21] = 58.317;",
"n[22] = 58.706;",
"n[23] = 59.095;",
"n[24] = 59.483;",
"n[25] = 59.871;",
"n[26] = 60.257;",
"n[27] = 60.642;",
"n[28] = 61.026;",
"n[29] = 61.409;",
"n[30] = 61.791;",
"n[31] = 62.172;",
"n[32] = 62.552;",
"n[33] = 62.93;",
"n[34] = 63.307;",
"n[35] = 63.683;",
"n[36] = 64.058;",
"n[37] = 64.431;",
"n[38] = 64.803;",
"n[39] = 65.173;",
"n[40] = 65.542;",
"n[41] = 65.91;",
"n[42] = 66.276;",
"n[43] = 66.64;",
"n[44] = 67.003;",
"n[45] = 67.364;",
"n[46] = 67.724;",
"n[47] = 68.082;",
"n[48] = 68.439;",
"n[49] = 68.793;",
"n[50] = 69.146;",
"n[51] = 69.497;",
"n[52] = 69.847;",
"n[53] = 70.194;",
"n[54] = 70.54;",
"n[55] = 70.884;",
"n[56] = 71.226;",
"n[57] = 71.566;",
"n[58] = 71.904;",
"n[59] = 72.24;",
"n[60] = 72.575;",
"n[61] = 72.907;",
"n[62] = 73.237;",
"n[63] = 73.565;",
"n[64] = 73.891;",
"n[65] = 74.215;",
"n[66] = 74.537;",
"n[67] = 74.857;",
"n[68] = 75.175;",
"n[69] = 75.49;",
"n[70] = 75.804;",
"n[71] = 76.115;",
"n[72] = 76.424;",
"n[73] = 76.73;",
"n[74] = 77.035;",
"n[75] = 77.337;",
"n[76] = 77.637;",
"n[77] = 77.935;",
"n[78] = 78.23;",
"n[79] = 78.524;",
"n[80] = 78.814;",
"n[81] = 79.103;",
"n[82] = 79.389;",
"n[83] = 79.673;",
"n[84] = 79.955;",
"n[85] = 80.234;",
"n[86] = 80.511;",
"n[87] = 80.785;",
"n[88] = 81.057;",
"n[89] = 81.327;",
"n[90] = 81.594;",
"n[91] = 81.859;",
"n[92] = 82.121;",
"n[93] = 82.381;",
"n[94] = 82.639;",
"n[95] = 82.894;",
"n[96] = 83.147;",
"n[97] = 83.398;",
"n[98] = 83.646;",
"n[99] = 83.891;",
"n[100] = 84.134;",
"n[101] = 84.375;",
"n[102] = 84.614;",
"n[103] = 84.849;",
"n[104] = 85.083;",
"n[105] = 85.314;",
"n[106] = 85.543;",
"n[107] = 85.769;",
"n[108] = 85.993;",
"n[109] = 86.214;",
"n[110] = 86.433;",
"n[111] = 86.65;",
"n[112] = 86.864;",
"n[113] = 87.076;",
"n[114] = 87.286;",
"n[115] = 87.493;",
"n[116] = 87.698;",
"n[117] = 87.9;",
"n[118] = 88.1;",
"n[119] = 88.298;",
"n[120] = 88.493;",
"n[121] = 88.686;",
"n[122] = 88.877;",
"n[123] = 89.065;",
"n[124] = 89.251;",
"n[125] = 89.435;",
"n[126] = 89.617;",
"n[127] = 89.796;",
"n[128] = 89.973;",
"n[129] = 90.147;",
"n[130] = 90.32;",
"n[131] = 90.49;",
"n[132] = 90.658;",
"n[133] = 90.824;",
"n[134] = 90.988;",
"n[135] = 91.149;",
"n[136] = 91.308;",
"n[137] = 91.466;",
"n[138] = 91.621;",
"n[139] = 91.774;",
"n[140] = 91.924;",
"n[141] = 92.073;",
"n[142] = 92.22;",
"n[143] = 92.364;",
"n[144] = 92.507;",
"n[145] = 92.647;",
"n[146] = 92.785;",
"n[147] = 92.922;",
"n[148] = 93.056;",
"n[149] = 93.189;",
"n[150] = 93.319;",
"n[151] = 93.448;",
"n[152] = 93.574;",
"n[153] = 93.699;",
"n[154] = 93.822;",
"n[155] = 93.943;",
"n[156] = 94.062;",
"n[157] = 94.179;",
"n[158] = 94.295;",
"n[159] = 94.408;",
"n[160] = 94.52;",
"n[161] = 94.63;",
"n[162] = 94.738;",
"n[163] = 94.845;",
"n[164] = 94.95;",
"n[165] = 95.053;",
"n[166] = 95.154;",
"n[167] = 95.254;",
"n[168] = 95.352;",
"n[169] = 95.449;",
"n[170] = 95.543;",
"n[171] = 95.637;",
"n[172] = 95.728;",
"n[173] = 95.818;",
"n[174] = 95.907;",
"n[175] = 95.994;",
"n[176] = 96.08;",
"n[177] = 96.164;",
"n[178] = 96.246;",
"n[179] = 96.327;",
"n[180] = 96.407;",
"n[181] = 96.485;",
"n[182] = 96.562;",
"n[183] = 96.638;",
"n[184] = 96.712;",
"n[185] = 96.784;",
"n[186] = 96.856;",
"n[187] = 96.926;",
"n[188] = 96.995;",
"n[189] = 97.062;",
"n[190] = 97.128;",
"n[191] = 97.193;",
"n[192] = 97.257;",
"n[193] = 97.32;",
"n[194] = 97.381;",
"n[195] = 97.441;",
"n[196] = 97.5;",
"n[197] = 97.558;",
"n[198] = 97.615;",
"n[199] = 97.67;",
"n[200] = 97.725;",
"n[201] = 97.778;",
"n[202] = 97.831;",
"n[203] = 97.882;",
"n[204] = 97.932;",
"n[205] = 97.982;",
"n[206] = 98.03;",
"n[207] = 98.077;",
"n[208] = 98.124;",
"n[209] = 98.169;",
"n[210] = 98.214;",
"n[211] = 98.257;",
"n[212] = 98.3;",
"n[213] = 98.341;",
"n[214] = 98.382;",
"n[215] = 98.422;",
"n[216] = 98.461;",
"n[217] = 98.5;",
"n[218] = 98.537;",
"n[219] = 98.574;",
"n[220] = 98.61;",
"n[221] = 98.645;",
"n[222] = 98.679;",
"n[223] = 98.713;",
"n[224] = 98.745;",
"n[225] = 98.778;",
"n[226] = 98.809;",
"n[227] = 98.84;",
"n[228] = 98.87;",
"n[229] = 98.899;",
"n[230] = 98.928;",
"n[231] = 98.956;",
"n[232] = 98.983;",
"n[233] = 99.01;",
"n[234] = 99.036;",
"n[235] = 99.061;",
"n[236] = 99.086;",
"n[237] = 99.111;",
"n[238] = 99.134;",
"n[239] = 99.158;",
"n[240] = 99.18;",
"n[241] = 99.202;",
"n[242] = 99.224;",
"n[243] = 99.245;",
"n[244] = 99.266;",
"n[245] = 99.286;",
"n[246] = 99.305;",
"n[247] = 99.324;",
"n[248] = 99.343;",
"n[249] = 99.361;",
"n[250] = 99.379;",
"n[251] = 99.396;",
"n[252] = 99.413;",
"n[253] = 99.43;",
"n[254] = 99.446;",
"n[255] = 99.461;",
"n[256] = 99.477;",
"n[257] = 99.492;",
"n[258] = 99.506;",
"n[259] = 99.52;",
"n[260] = 99.534;",
"n[261] = 99.547;",
"n[262] = 99.56;",
"n[263] = 99.573;",
"n[264] = 99.585;",
"n[265] = 99.598;",
"n[266] = 99.609;",
"n[267] = 99.621;",
"n[268] = 99.632;",
"n[269] = 99.643;",
"n[270] = 99.653;",
"n[271] = 99.664;",
"n[272] = 99.674;",
"n[273] = 99.683;",
"n[274] = 99.693;",
"n[275] = 99.702;",
"n[276] = 99.711;",
"n[277] = 99.72;",
"n[278] = 99.728;",
"n[279] = 99.736;",
"n[280] = 99.744;",
"n[281] = 99.752;",
"n[282] = 99.76;",
"n[283] = 99.767;",
"n[284] = 99.774;",
"n[285] = 99.781;",
"n[286] = 99.788;",
"n[287] = 99.795;",
"n[288] = 99.801;",
"n[289] = 99.807;",
"n[290] = 99.813;",
"n[291] = 99.819;",
"n[292] = 99.825;",
"n[293] = 99.831;",
"n[294] = 99.836;",
"n[295] = 99.841;",
"n[296] = 99.846;",
"n[297] = 99.851;",
"n[298] = 99.856;",
"n[299] = 99.861;",
"n[300] = 99.865;",
"n[301] = 99.869;",
"n[302] = 99.874;",
"n[303] = 99.878;",
"n[304] = 99.882;",
"n[305] = 99.886;",
"n[306] = 99.889;",
"n[307] = 99.893;",
"n[308] = 99.896;",
"n[309] = 99.9;",
"",
"function ZtoPercentile(z){",
"with (document.CDCInfantHeadCircForAge_form){",
"az = Math.abs(z);",
"if (z < -3.09) return 0.1;",
"if (z > 3.09) return 99.9;",
"thispercentile = n[Math.round(az * 100)];",
"if (z >= 0) { return thispercentile }",
"else { return 100 - thispercentile }",
"}}",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function CDCInfantHeadCircForAge_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.CDCInfantHeadCircForAge_form){",
"",
"",
"doCalc = true;",
"if (Sex_radio[0].checked){ Sex = 1; }",
"if (Sex_radio[1].checked){ Sex = 2; }",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Head_Circumference_param.value.indexOf(',') >= 0){ Head_Circumference_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Head_Circumference_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Head_Circumference_unit.options[Head_Circumference_unit.selectedIndex].value.split('|');",
"Head_Circumference = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"if(Sex == 1){",
"if(Age >= 0 && Age < 1){L = -1.440271514; M = 36.03453876; S = 0.042999604;};",
"if(Age >= 1 && Age < 2){L = -1.581016348; M = 37.97671987; S = 0.038067862;};",
"if(Age >= 2 && Age < 3){L = -1.593136386; M = 39.3801263; S = 0.035079612;};",
"if(Age >= 3 && Age < 4){L = -1.521492427; M = 40.46773733; S = 0.033096443;};",
"if(Age >= 4 && Age < 5){L = -1.394565915; M = 41.34841008; S = 0.03170963;};",
"if(Age >= 5 && Age < 6){L = -1.231713389; M = 42.0833507; S = 0.030709039;};",
"if(Age >= 6 && Age < 7){L = -1.046582628; M = 42.71033603; S = 0.029974303;};",
"if(Age >= 7 && Age < 8){L = -0.848932692; M = 43.25428882; S = 0.029430992;};",
"if(Age >= 8 && Age < 9){L = -0.645779124; M = 43.73249646; S = 0.029030379;};",
"if(Age >= 9 && Age < 10){L = -0.442165412; M = 44.15742837; S = 0.028739112;};",
"if(Age >= 10 && Age < 11){L = -0.24163206; M = 44.53836794; S = 0.028533537;};",
"if(Age >= 11 && Age < 12){L = -0.046673786; M = 44.88240562; S = 0.028396382;};",
"if(Age >= 12 && Age < 13){L = 0.141031094; M = 45.19507651; S = 0.028314722;};",
"if(Age >= 13 && Age < 14){L = 0.320403169; M = 45.48078147; S = 0.028278682;};",
"if(Age >= 14 && Age < 15){L = 0.490807133; M = 45.74307527; S = 0.028280585;};",
"if(Age >= 15 && Age < 16){L = 0.65193505; M = 45.98486901; S = 0.028314363;};",
"if(Age >= 16 && Age < 17){L = 0.803718086; M = 46.20857558; S = 0.028375159;};",
"if(Age >= 17 && Age < 18){L = 0.946259679; M = 46.41621635; S = 0.028459033;};",
"if(Age >= 18 && Age < 19){L = 1.079784984; M = 46.60950084; S = 0.028562759;};",
"if(Age >= 19 && Age < 20){L = 1.204602687; M = 46.78988722; S = 0.028683666;};",
"if(Age >= 20 && Age < 21){L = 1.321076285; M = 46.95862881; S = 0.028819525;};",
"if(Age >= 21 && Age < 22){L = 1.429602576; M = 47.11681039; S = 0.028968459;};",
"if(Age >= 22 && Age < 23){L = 1.530595677; M = 47.26537682; S = 0.029128879;};",
"if(Age >= 23 && Age < 24){L = 1.624475262; M = 47.40515585; S = 0.029299426;};",
"if(Age >= 24 && Age < 25){L = 1.71165803; M = 47.53687649; S = 0.029478937;};",
"if(Age >= 25 && Age < 26){L = 1.792551616; M = 47.66118396; S = 0.029666406;};",
"if(Age >= 26 && Age < 27){L = 1.867550375; M = 47.77865186; S = 0.02986096;};",
"if(Age >= 27 && Age < 28){L = 1.93703258; M = 47.8897923; S = 0.030061839;};",
"if(Age >= 28 && Age < 29){L = 2.001358669; M = 47.99506422; S = 0.030268375;};",
"if(Age >= 29 && Age < 30){L = 2.060870301; M = 48.09488048; S = 0.030479985;};",
"if(Age >= 30 && Age < 31){L = 2.115889982; M = 48.18961365; S = 0.03069615;};",
"if(Age >= 31 && Age < 32){L = 2.16672113; M = 48.2796011; S = 0.030916413;};",
"if(Age >= 32 && Age < 33){L = 2.21364844; M = 48.36514917; S = 0.031140368;};",
"if(Age >= 33 && Age < 34){L = 2.256943216; M = 48.44653703; S = 0.031367651;};",
"if(Age >= 34 && Age < 35){L = 2.296844024; M = 48.52401894; S = 0.031597939;};",
"if(Age >= 35 && Age < 36){L = 2.333589434; M = 48.59782828; S = 0.031830942;};",
"}",
"if (Sex == 2){",
"if(Age >= 0 && Age < 1){L = 4.310927464; M = 37.19361054; S = 0.047259148;};",
"if(Age >= 1 && Age < 2){L = 3.869576802; M = 39.20742929; S = 0.040947903;};",
"if(Age >= 2 && Age < 3){L = 3.305593039; M = 40.65233195; S = 0.037027722;};",
"if(Age >= 3 && Age < 4){L = 2.720590297; M = 41.76516959; S = 0.034364245;};",
"if(Age >= 4 && Age < 5){L = 2.16804824; M = 42.66116148; S = 0.032462175;};",
"if(Age >= 5 && Age < 6){L = 1.675465689; M = 43.40488731; S = 0.031064702;};",
"if(Age >= 6 && Age < 7){L = 1.255160322; M = 44.03609923; S = 0.03002267;};",
"if(Age >= 7 && Age < 8){L = 0.91054114; M = 44.58096912; S = 0.029242173;};",
"if(Age >= 8 && Age < 9){L = 0.639510474; M = 45.05761215; S = 0.028660454;};",
"if(Age >= 9 && Age < 10){L = 0.436978864; M = 45.4790756; S = 0.0282336;};",
"if(Age >= 10 && Age < 11){L = 0.296275856; M = 45.85505706; S = 0.027929764;};",
"if(Age >= 11 && Age < 12){L = 0.210107251; M = 46.19295427; S = 0.027725179;};",
"if(Age >= 12 && Age < 13){L = 0.171147024; M = 46.49853438; S = 0.027601686;};",
"if(Age >= 13 && Age < 14){L = 0.172393886; M = 46.77637684; S = 0.027545148;};",
"if(Age >= 14 && Age < 15){L = 0.207371541; M = 47.03017599; S = 0.027544382;};",
"if(Age >= 15 && Age < 16){L = 0.270226126; M = 47.2629533; S = 0.027590417;};",
"if(Age >= 16 && Age < 17){L = 0.355757274; M = 47.47720989; S = 0.02767598;};",
"if(Age >= 17 && Age < 18){L = 0.459407627; M = 47.67503833; S = 0.027795115;};",
"if(Age >= 18 && Age < 19){L = 0.577227615; M = 47.85820606; S = 0.0279429;};",
"if(Age >= 19 && Age < 20){L = 0.705826778; M = 48.02821867; S = 0.028115241;};",
"if(Age >= 20 && Age < 21){L = 0.842319055; M = 48.18636864; S = 0.028308707;};",
"if(Age >= 21 && Age < 22){L = 0.984266833; M = 48.3337732; S = 0.028520407;};",
"if(Age >= 22 && Age < 23){L = 1.129626698; M = 48.47140432; S = 0.028747896;};",
"if(Age >= 23 && Age < 24){L = 1.276691223; M = 48.60011223; S = 0.028989089;};",
"if(Age >= 24 && Age < 25){L = 1.424084853; M = 48.72064621; S = 0.029242207;};",
"if(Age >= 25 && Age < 26){L = 1.570621291; M = 48.83366629; S = 0.029505723;};",
"if(Age >= 26 && Age < 27){L = 1.715393998; M = 48.93976089; S = 0.029778323;};",
"if(Age >= 27 && Age < 28){L = 1.857652984; M = 49.03945383; S = 0.030058871;};",
"if(Age >= 28 && Age < 29){L = 1.996810563; M = 49.13321432; S = 0.030346384;};",
"if(Age >= 29 && Age < 30){L = 2.132411346; M = 49.22146409; S = 0.030640006;};",
"if(Age >= 30 && Age < 31){L = 2.264111009; M = 49.30458348; S = 0.030938992;};",
"if(Age >= 31 && Age < 32){L = 2.391658052; M = 49.38291658; S = 0.031242693;};",
"if(Age >= 32 && Age < 33){L = 2.514878222; M = 49.45677569; S = 0.031550537;};",
"if(Age >= 33 && Age < 34){L = 2.633661226; M = 49.526445; S = 0.031862026;};",
"if(Age >= 34 && Age < 35){L = 2.747949445; M = 49.59218385; S = 0.03217672;};",
"if(Age >= 35 && Age < 36){L = 2.857728375; M = 49.65422952; S = 0.032494231;};",
"}",
"Z_Score =  (power((Head_Circumference / M), L) - 1) / (L * S);",
"",
"if (doCalc) Z_Score_param.value = fixDP(Z_Score, dp);",
"",
"",
"",
"Percentile =  ZtoPercentile(Z_Score);",
"",
"if (doCalc) Percentile_param.value = fixDP(Percentile, dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (Percentile < 3){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Percentile >= 3) && (Percentile < 97)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (Percentile >= 97){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CDCInfantHeadCircForAge_form){",
"",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 mo.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 35.99) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 35.99 mo.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Head_Circumference_param.value && Head_Circumference < 20) {",
"Head_Circumference = 0;",
"Head_Circumference_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Head Circumference is 20 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Head_Circumference_param.value && Head_Circumference > 200) {",
"Head_Circumference_param.value = \"\";",
"clrResults();",
"Head_Circumference = 0;",
"doCalc = false;",
"alert(\"The maximum value for Head Circumference is 200 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CDCInfantHeadCircForAge_form){",
"",
"Z_Score_param.value = '';",
"Percentile_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f16_25_16788=null;
var title_f16_25_16789="Mipomersen: Drug information";
var content_f16_25_16789=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mipomersen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/12/3269?source=see_link\">",
"    see \"Mipomersen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F16060082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16128039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kynamro&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16060085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antihyperlipidemic Agent, Apolipoprotein B Antisense Oligonucleotide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16265728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Homozygous familial hypercholesterolemia (HoFH):",
"     </b>",
"     SubQ: 200 mg once weekly.",
"     <b>",
"      Note:",
"     </b>",
"     Maximal LDL-C reduction seen after ~6 months.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16265729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16265730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use is not recommended in patients with severe renal impairment, clinically significant proteinuria, or receiving hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use is contraindicated in patients	 with moderate or severe hepatic impairment (Child-Pugh class B or C), active liver disease, or unexplained persistent elevations of hepatic transaminases.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F16265723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      ALT or AST &ge;3 x and &lt;5 x ULN:",
"     </b>",
"     First, repeat measurement within 1 week to confirm elevation. Once confirmed, withhold mipomersen and obtain additional liver function tests (eg, total bilirubin, alkaline phosphatase, and INR); investigate for probable cause.  If resumed when AST or ALT &lt;3 x ULN, monitor liver function tests more frequently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      ALT or AST &ge;5 x ULN:",
"     </b>",
"     Withhold mipomersen and obtain additional liver function tests (eg, total bilirubin, alkaline phosphatase, and INR); investigate for probable cause.  If resumed when AST or ALT &lt;3 x ULN, monitor liver function tests more frequently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Clinical symptoms of liver injury (eg, nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms), bilirubin increase &ge;2 x ULN, or active liver disease:",
"     </b>",
"     Discontinue mipomersen; investigate for probable cause.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16128040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kynamro&trade;: 200 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F16265686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Prescribers must enroll in the Kynamro&trade; REMS program and complete the prescriber training and complete, sign, and submit the Prescriber Enrollment Form to the Kynamro &trade; REMS program. The prescriber must then complete the Prescriber Training before activation within the Kynamro&trade; REMS program. Pharmacies must educate all pharmacy staff involved in the dispensing of Kynamro&trade; on the REMS program requirements, put processes in place to verify (prior to dispensing Kynamro&trade;) that the prescriber is certified and the Prescription Authorization Form is received with each new prescription. Pharmacies must also agree to be audited to ensure that all processes and procedures in place are being followed in accordance with the program and be able to provide prescription data to the REMS program.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F16132307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM337730.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM337730.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16316882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      For subQ administration only. Do not administer I.M. or I.V.",
"     </b>",
"     Remove from refrigerator, allow to reach room temperature (&ge;30 minutes prior to administration), and visually inspect prior to administration; do not administer if solution is cloudy or contains visible particulate matter (return to pharmacy). Administer first injection under the guidance/supervision of a qualified health care professional.  Administer SubQ into the abdomen, thigh region, or outer area of upper arm; do not administer where there is active skin disease (eg, sunburns, skin rash, inflammation/infection) or into tattooed skin or scar. Administer on the same day every week. If dose is missed, administer at least 3 days before the next weekly dose.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16060087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy and other lipid-lowering treatments to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16249390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (15%), headache (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (&ge;3 x ULN to &lt;5 x ULN: 12%; &ge;5 x ULN to &lt;10 x ULN: 3%; &ge;10 x ULN: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions: Erythema (59%), pain (56%), hematoma (32%), pruritus (29%), swelling (18%), discoloration (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody formation (38% to 72%), flu-like syndrome (13% to 66%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (7%), peripheral edema (5%), angina pectoris (4%), palpitations (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (8%), chills (6%), insomnia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (4%), abdominal pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hepatic steatosis (7%), AST increased (&ge;3 x ULN to &lt;5 x ULN: 7%; &ge;5 x ULN to &lt;10 x ULN: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Limb pain (7%), musculoskeletal pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Proteinuria (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Neoplasms (4%, benign and malignant)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, glomerular nephritis, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16265691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mipomersen or any component of the formulation; moderate or severe hepatic impairment (Child-Pugh class B or C); active liver disease; unexplained persistent elevations of hepatic transaminases",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16265692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: As seen in clinical trials, may cause hepatic transaminase elevation and increases in hepatic steatosis (with or without concomitant increases in transaminases) which may progress to steatohepatitis and cirrhosis; measure ALT, AST, alkaline phosphatase, and total bilirubin prior to initiation, then ALT and AST on a regular basis as recommended. Withhold dose of mipomersen if ALT or AST is &ge;3 x ULN. Discontinue mipomersen if clinically significant hepatotoxicity occurs. Because mipomersen has a risk of hepatotoxicity, it is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) program (Kynamro&trade; REMS).",
"     </b>",
"     Alcohol consumption during treatment with mipomersen should be limited to &le;1 drink/day due to potential to increase levels of hepatic fat and induce or exacerbate liver injury. Use caution when used concomitantly with other medications known to cause hepatotoxicity (eg, isotretinoin, amiodarone, acetaminophen [&gt;4 g/day for &ge;3 days/week]). Use is contraindicated in patients with moderate or severe hepatic impairment or active liver disease including patients with unexplained persistent elevations of hepatic transaminases. If baseline liver function tests are abnormal, consider initiation after an appropriate work up and abnormalities are explained or resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Influenza-like symptoms: Within 2 days after an injection, influenza-like symptoms (eg, fever, chills, myalgia, arthralgia, malaise, or fatigue) have been reported in 30% of patients receiving mipomersen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Injection site reactions: Injection site reactions (eg, erythema, pain, tenderness, pruritus, and local swelling) were common in patients receiving mipomersen; minimize injection site reactions by using proper subcutaneous administration technique.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment:  Safety and efficacy in patients with hepatic impairment have not been established; use is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh class B or C), active liver disease, or unexplained persistent elevations of hepatic transaminases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Safety and efficacy in patients with renal impairment including those who undergo hemodialysis have not been established; use is not recommended in patients with severe renal impairment, clinically significant proteinuria, or on hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxic medications: Use with caution in patients receiving concomitant medications known to cause hepatotoxicity (eg, isotretinoin, amiodarone, acetaminophen [&gt;4 g/day for &ge;3 days/week], methotrexate, tetracyclines, and tamoxifen); consider monitoring liver function tests more frequently.  Concurrent use with LDL-C lowering medications that can also increase hepatic fat is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: In clinical trials, patients &ge;65 years of age (n=59) experienced a higher incidence of hepatic steatosis, hypertension, and peripheral edema; use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Safety and efficacy of the treatment of hypercholesterolemia not due to homozygous familial hypercholesterolemia (HoFH) have not been established. The use of mipomersen as an adjunct to LDL-C apheresis is not recommended (use not established).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16265522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16265520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the hepatotoxic effect of Mipomersen. Management: Patients being treated with mipomersen should limit their consumption of alcohol to a maximum of 1 drink (or equivalent) per day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ISOtretinoin: May enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Mipomersen may enhance the hepatotoxic effect of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: May enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F16265696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Limit alcohol consumption during treatment with mipomersen to &le;1 drink/day due to potential for increased levels of hepatic fat and induced or exacerbated liver injury.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16265687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16265688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16265689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if mipomersen is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F16316881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Limit alcohol consumption during treatment with mipomersen to &le;1 drink/day due to potential for increased levels of hepatic fat and induced or exacerbated liver injury.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Kynamro Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/mL (1 mL): $4067.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16316884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     At baseline measure ALT, AST, total bilirubin, alkaline phosphatase, then monthly for the first year of treatment, followed by every 3 months (or more frequently if clinically indicated) after the first year; lipid levels (total cholesterol [C], LDL-C, HDL-C, triglycerides) at least every 3 months for the first year",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16265699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mipomersen is an oligonucleotide inhibitor of apo B-100 synthesis. ApoB is the main component of LDL-C and very low density lipoprotein (VLDL), which is the precursor to LDL-C. Mipomersen binds to the messenger ribonucleic acid (mRNA) of apoB in a sequence-specific manner which results in degradation (RNase H-mediated) or disruption of the mRNA thereby reducing formation of apoB.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16265701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &ge;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Metabolized in tissues by endonucleases to form shorter oligonucleotides available for further metabolism by exonucleases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 54% to 78% (dose-dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 1-2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Mipomersen, metabolic byproducts (ie, shorter oligonucleotides): Within 24 hours after administration: Urine &lt;4%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Raal FJ, Santos RD, Blom DJ, et al, &ldquo;Mipomersen, an Apolipoprotein B Synthesis Inhibitor, for Lowering of LDL Cholesterol Concentrations in Patients With Homozygous Familial Hypercholesterolaemia: A Randomised, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 375(9719):998-1006.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16789/abstract-text/20227758/pubmed\" id=\"20227758\" target=\"_blank\">",
"        20227758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87807 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16789=[""].join("\n");
var outline_f16_25_16789=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16060082\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16128039\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16060085\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265728\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265729\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265730\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265731\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265723\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16128040\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265686\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16132307\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16316882\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16060087\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16249390\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265691\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265692\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265522\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265520\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265696\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265687\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265688\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265689\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265690\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16316881\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570470\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16316884\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265699\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265701\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87807\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87807|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/12/3269?source=related_link\">",
"      Mipomersen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_25_16790="Antiphospholipid antibody syndrome purpura";
var content_f16_25_16790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65890%7EDERM%2F65011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65890%7EDERM%2F65011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Purpura in antiphospholipid antibody syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Noninflammatory, retiform purpura are present on the buttocks and thighs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Purpura in antiphospholipid antibody syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retiform purpura are present on the buttock.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16790=[""].join("\n");
var outline_f16_25_16790=null;
var title_f16_25_16791="Moexipril and hydrochlorothiazide: Drug information";
var content_f16_25_16791=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Moexipril and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/9/27797?source=see_link\">",
"    see \"Moexipril and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Uniretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Uniretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F198353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F198341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 7.5-30 mg of moexipril, taken either in a single or divided dose 1 hour before meals; hydrochlorothiazide dose should be &le;50 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F198342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Overall safety and efficacy are not different in elderly patients, although a higher moexipril AUC was observed in elderly patients. Greater sensitivity to effects may be observed in some older individuals. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5/12.5: Moexipril hydrochloride 7.5 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15/12.5: Moexipril hydrochloride 15 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15/25: Moexipril hydrochloride 15 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Uniretic&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5/12.5: Moexipril hydrochloride 7.5 mg and hydrochlorothiazide 12.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15/12.5: Moexipril hydrochloride 15 mg and hydrochlorothiazide 12.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15/25: Moexipril hydrochloride 15 mg and hydrochlorothiazide 25 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F198328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; not indicated for initial treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F198351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F198331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to moexipril, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F198318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose), angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use ACE inhibitors with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Hydrochlorothiazide can cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use moexipril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use ACE inhibitors with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective). Contraindicated in anuric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F198334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F198344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F198333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Moexipril-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-12.5 mg (100): $133.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-12.5 mg (100): $133.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-25 mg (100): $133.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Uniretic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-12.5 mg (100): $300.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-12.5 mg (100): $300.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-25 mg (100): $300.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6179223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, BUN, serum creatinine, and electrolytes; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F198335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fempress Plus (DE);",
"     </li>",
"     <li>",
"      Moex Plus (BG);",
"     </li>",
"     <li>",
"      Uniretic (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F198317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F198330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16791/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16791/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16791/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9748 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-BD8FD8CCCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16791=[""].join("\n");
var outline_f16_25_16791=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709146\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198337\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198338\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198353\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198341\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198342\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198326\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198314\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198328\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198351\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198331\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198318\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299724\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198322\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198323\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198334\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198344\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198333\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6179223\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198335\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198317\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198330\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9748\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9748|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/9/27797?source=related_link\">",
"      Moexipril and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_25_16792="Fixed drug eruption arm";
var content_f16_25_16792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52192%7EDERM%2F65991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52192%7EDERM%2F65991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fixed drug eruption. An oval lesion occurred at the identical site where it had occurred previously. In both episodes, the rash emerged after this patient ingested a sulfonamide antibiotic. Note the eroded blister in the center of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fixed drug eruption. An oval erosion on the glans penis occurred in this patient who was taking minocycline. According to the patient, an identical lesion appeared when he was given minocycline previously.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16792=[""].join("\n");
var outline_f16_25_16792=null;
var title_f16_25_16793="Lenalidomide: Drug information";
var content_f16_25_16793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lenalidomide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/39/11894?source=see_link\">",
"    see \"Lenalidomide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2407571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Revlimid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6027963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Revlimid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2407576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiogenesis Inhibitor;",
"     </li>",
"     <li>",
"      Antineoplastic Agent;",
"     </li>",
"     <li>",
"      Immunomodulator, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2407611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Multiple myeloma:",
"     </b>",
"     Oral: 25 mg once daily for 21 days of a 28-day treatment cycle (in combination with dexamethasone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Myelodysplastic syndrome (MDS) with deletion 5q:",
"     </b>",
"     Oral: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diffuse large B-cell lymphoma, relapsed/refractory (unlabeled use):",
"     </b>",
"     Oral: 25 mg once daily for 21 days of a 28-day treatment cycle for up to 1 year (Wiernik, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mantle cell lymphoma, relapsed or refractory (unlabeled use):",
"     </b>",
"     Oral: 25 mg once daily for 21 days of a 28-day treatment cycle for up to 1 year (Habermann, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Multiple myeloma, induction (unlabeled use):",
"     </b>",
"     Oral: 25 mg once daily for 14 days of a 21-day cycle (in combination with bortezomib and dexamethasone) for 8 cycles (Kumar, 2012; Richardson, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Multiple myeloma, maintenance (following autologous stem cell transplant; unlabeled use):",
"     </b>",
"     Oral: 10 mg once daily for 3 months, then increased to 15 mg daily if tolerated; continue until relapse (Attal, 2012; McCarthy, 2012)",
"     <b>",
"      or",
"     </b>",
"     10 mg once daily for 21 days of a 28-day treatment cycle until relapse (Palumbo, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Myelodysplastic syndrome (MDS), lower risk, without deletion 5q (unlabeled use):",
"     </b>",
"     Oral: 10 mg once daily (Raza, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2407612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Due to the potential for decreased renal function in the elderly, select dose carefully and closely monitor renal function.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2407613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Recommended initial dose adjustment in the FDA-approved labeling; further individualize based on tolerance:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     MDS:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (nondialysis dependent): 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ESRD: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and dialysis dependent: 2.5 mg once daily (administer after dialysis on dialysis days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Multiple myeloma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: 10 mg once daily (may increase to 15 mg once daily after 2 cycles if nonresponsive but tolerating treatment; Chen, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (nondialysis dependent): 15 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ESRD: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and dialysis dependent: 5 mg once daily (administer after dialysis on dialysis days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Recommended adjustment in Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     MDS:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (nondialysis dependent): 5 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ESRD: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and dialysis dependent: 5 mg 3 times weekly (administer after each dialysis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Multiple myeloma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute: 10 mg once daily; (may increase to 15 mg once daily after 2 cycles if nonresponsive but tolerating treatment; Chen, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (nondialysis dependent): 15 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ESRD: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and dialysis dependent: 5 mg once daily (administer after dialysis on dialysis days)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, lenalidomide undergoes minimal hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F2407614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      NONHEMATOLOGIC toxicities:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Dermatologic toxicities:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Skin rash, grade 2 or 3: Consider interrupting or discontinuing treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Angioedema, grade 4 rash, exfoliative or bullous rash, or suspected Stevens-Johnson syndrome or toxic epidermal necrolysis: Discontinue treatment; do not rechallenge",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Other toxicities:",
"     </i>",
"     For additional treatment-related grade 3/4 toxicities, hold treatment and restart at next lower dose level when toxicity has resolved to &le;grade 2.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      HEMATOLOGIC toxicities:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adjustment for thrombocytopenia in MDS:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Thrombocytopenia developing within 4 weeks of beginning treatment at 10 mg daily:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Baseline platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     When platelets return to &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume treatment at 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Baseline platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If platelets fall to 50% of baseline: Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If baseline &ge;60,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet level returns to &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume at 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If baseline &lt;60,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet level returns to &ge;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume at 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Thrombocytopenia developing after 4 weeks of beginning treatment at 10 mg daily:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets &lt;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with platelet transfusions: Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     When platelets return to &ge;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (without hemostatic failure): Resume at 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Thrombocytopenia developing with treatment at 5 mg daily:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets &lt;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with platelet transfusions: Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     When platelets return to &ge;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (without hemostatic failure):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     U.S. labeling: Resume at 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Canadian labeling: Resume at 5 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Adjustment for neutropenia in MDS:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Neutropenia developing within 4 weeks of beginning treatment at 10 mg daily:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     For baseline absolute neutrophil count (ANC) &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     When ANC returns to &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume at 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     For baseline absolute neutrophil count (ANC) &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     When ANC returns to &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume at 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Neutropenia developing after 4 weeks of beginning treatment at 10 mg daily:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &ge;7 days or associated with fever: Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     When ANC returns to &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume at 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Neutropenia developing with treatment at 5 mg daily:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &ge;7 days or associated with fever: Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     When ANC returns to &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     U.S. labeling: Resume at 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Canadian labeling: Resume at 5 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Adjustment for thrombocytopenia in multiple myeloma:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Platelets &lt;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold treatment, check CBC weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     When platelets return to &ge;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume at 15 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Additional occurrence of platelets &lt;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     When platelets return to &ge;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume treatment at 5 mg below previous dose; do not dose below 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Adjustment for neutropenia in multiple myeloma:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold treatment, add G-CSF, check CBC weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     When ANC returns to &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (with neutropenia as only toxicity): Resume at 25 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     When ANC returns to  &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (with additional toxicities): Resume at 15 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Additional occurrence of ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     When ANC returns to &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume treatment at 5 mg below previous dose; do not dose below 5 mg daily.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2407623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Revlimid&reg;: 2.5 mg, 5 mg, 10 mg, 15 mg, 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2407574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Lenalidomide is approved for marketing in the U.S. only under a Food and Drug Administration (FDA) approved, restricted distribution program called Revlimid REMS&trade;  (www.celgeneriskmanagment.com or 1-888-423-5436). Prescriptions must be filled within 7 days (for females of reproductive potential) or within 30 days (for all other patients) after authorization number obtained. Subsequent prescriptions may be filled only if fewer than 7 days of therapy remain on the previous prescription. A new prescription is required for further dispensing (a telephone prescription may not be accepted.) Pregnancy testing is required for females of childbearing potential. In Canada, distribution is restricted through RevAid&reg; (www.RevAid.ca or 1-888-738-2431).",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111335.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111335.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2407615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with water; may administer with or without food. Swallow capsule whole; do not break, open, or chew.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     May administer a missed dose if within 12 hours of usual dosing time. If greater than 12 hours, patient should skip dose for that day and resume usual dosing the following day. Patient should",
"     <b>",
"      not",
"     </b>",
"     take 2 doses to make up for a missed dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2407578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of low- or intermediate-1-risk myelodysplastic syndrome (MDS) in patients with deletion 5q (del 5q) cytogenetic abnormality (with or without other cytogenetic abnormalities) with transfusion-dependent anemia; treatment of multiple myeloma (in combination with dexamethasone) in patients who have received at least one prior therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2407579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of non-Hodgkin&rsquo;s lymphomas; systemic light chain amyloidosis; lower-risk myelodysplastic syndrome (MDS) in transfusion-dependent patients without deletion 5q (del 5q); maintenance treatment for multiple myeloma (after response to primary treatment or following autologous stem cell transplant)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lenalidomide may be confused with leflunomide, pomalidomide, thalidomide",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2407591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (8% to 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (31% to 44%), fever (21% to 28%), dizziness (20% to 23%), headache (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (8% to 42%), rash (21% to 36%; grades 3/4: 7%), dry skin (9% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (11% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (39% to 49%), constipation (24% to 41%), nausea (24% to 26%), weight loss (20%), anorexia (10% to 16%), taste perversion (6% to 15%), vomiting (10% to 12%), abdominal pain (8% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (22% to 62%; grades 3/4: 12% to 50%; MDS: onset: 28 days [range 8-290 days]; recovery: 22 days [range: 5-224 days]), neutropenia (42% to 59%; grades 3/4: 33% to 53%; MDS: onset: 42 days [range 14-411 days]; recovery: 17 days [range: 2-170 days]), anemia (12% to 31%; grades 3/4: 6% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle cramp (18% to 33%), weakness (15%), arthralgia (22%), back pain (21% to 26%), tremor (21%), bone pain (14%), limb pain (11% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (15% to 25%), nasopharyngitis (18% to 23%), cough (&le;20%), dyspnea (7% to 24%), pharyngitis (14% to 16%), epistaxis (15%), pneumonia (9% to 14%), bronchitis (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (10%), deep vein thrombosis (&le;9%; grades 3/4: &le;8%), hypertension (6% to 8%), hypotension (7%), chest pain (5% to 8%), palpitation (5%), atrial fibrillation (grades 3/4: &le;4%), syncope (grade 3/4: 1% to 3%), cerebrovascular accident (2%), tachycardia (grades 3/4: 2%), angina pectoris (&ge;1%), bradycardia (&ge;1%), cerebral ischemia (&ge;1%), MI (&ge;1%), heart failure (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (10%), hypoesthesia (7% to 10%), lethargy (7%), pain (7%), depression (5%), hallucinations (&ge;1%), malaise (&ge;1%), mood swings (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising (5% to 8%), cellulitis (5%), erythema (5%), exanthem (&ge;1%), hirsutism (&ge;1%), hyperpigmentation (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypothyroidism (7%), hypomagnesemia (6% to 7%), hypocalcemia (9%), dehydration (7%), hypophosphatemia (grades 3/4: 3%), loss of libido (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Appetite decreased (7%), xerostomia (7%), loose stools (6%), glossodynia (&ge;1%), GI hemorrhage (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Dysuria (7%), erectile dysfunction (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Leukopenia (8%; grade 3/4: 4% to 5%), febrile neutropenia (5%; grades 3/4: 2% to 4%), granulocytopenia (grades 3/4: 2%), lymphopenia (5%; grade 3: 3%), pancytopenia (grades 3/4: 2%), autoimmune hemolytic anemia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (8%), liver function tests abnormal (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Myalgia (9%), neuropathy (5% to 7%), rigors (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Cataract (grades 3/4: 1% to 2%), blindness (&ge;1%), ocular hypertension (&ge;1%),",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Sinusitis (7% to 8%), rhinitis (7%), pulmonary embolism (&le;4%; grades 3/4: 2% to 4%), respiratory distress (grades 3/4: 1% to 2%), hoarseness (&ge;1%), hypoxia (grades 3/4: 1%), pleural effusion (grades 3/4: 1%), pneumonitis (grades 3/4: 1%), pulmonary hypertension (grades 3/4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Diaphoresis (7% to 10%), night sweats (8%), sepsis (grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute febrile neutrophilic dermatosis, acute leukemia, acute myeloid leukemia (AML), adrenal insufficiency, allergic reaction, angioedema, atrial flutter, azotemia, Basedow&rsquo;s disease, biliary obstruction, blindness, bone marrow depression, brain edema, cardiac failure, cardiogenic shock, cardiomyopathy, cardiopulmonary arrest, cholecystitis, chondrocalcinosis, chronic obstructive airway disease, circulatory collapse, coagulopathy, colonic polyp, delirium, diabetes mellitus, diabetic ketoacidosis, diverticulitis, dysphagia, encephalitis, erythema multiforme, Fanconi syndrome, gout, hematuria, hemolysis, hemolytic anemia, hemorrhage, hepatic failure, hepatitis, herpesvirus infection, hyperbilirubinemia, hypernatremia, hypersensitivity, hypoglycemia, infection, interstitial lung disease, intestinal perforation, intracranial hemorrhage, ischemia, ischemic colitis, leukoencephalopathy, liver failure, lung cancer, lung infiltration, lymphoma, myopathy, neutropenic sepsis, orthostatic hypotension, pancreatitis, peripheral ischemia, pneumonitis, pseudomembraneous colitis, pulmonary edema, refractory anemia, renal calculus, renal failure, renal mass, renal tubular necrosis, respiratory failure, secondary malignancy (AML, lymphomas, solid tumors, skin cancers), septic shock, serum creatinine increased, skin desquamation, small bowel obstruction, spinal cord compression, splenic infarction, Stevens-Johnson syndrome, stomatitis, supraventricular arrhythmia, tachyarrhythmia, thrombophlebitis, toxic epidermal necrolysis, troponin I increased, tumor flare, tumor lysis syndrome, urinary retention, urosepsis, urticaria, ventricular dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2407586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide or any component of the formulation; pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (in MDS patients); hypersensitivity to thalidomide; women capable of becoming pregnant; breast-feeding women",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2407587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Hematologic toxicity (neutropenia and thrombocytopenia) occurs in a majority of patients (grade 3/4: 80% in patients with del 5q myelodysplastic syndrome) and may require dose reductions and/or delays; the use of blood product support and/or growth factors may be needed. CBC should be monitored weekly for the first 8 weeks and at least monthly thereafter in patients being treated for del 5q myelodysplastic syndromes.",
"     </b>",
"     In patients being treated for multiple myeloma, monitor CBC every 2 weeks for 12 weeks and monthly thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause dizziness or fatigue; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Angioedema, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported; may be fatal. Consider interrupting or discontinuing treatment with grade 2 or 3 skin rash; discontinue and do not reinitiate treatment with angioedema, grade 4 rash, exfoliative or bullous rash, or for suspected SJS or TEN. Patients with a history of grade 4 rash with thalidomide should not receive lenalidomide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Transient abnormal hepatic laboratory findings (eg, increased transaminases) have been reported; interrupt therapy in patients with abnormal hepatic function tests. May resume treatment upon return to baseline. Successful rechallenge has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy: Second primary malignancies (SPMs), including hematologic (AML and lymphoma) and solid tumor malignancies, and skin cancers, have been reported with lenalidomide when used for the treatment of MDS and multiple myeloma; the incidence may be higher when lenalidomide is used in combination with an alkylating agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events:",
"     <b>",
"      [U.S. Boxed Warning]: Lenalidomide has been associated with a significant increase in risk for thrombosis and embolism in multiple myeloma patients treated with lenalidomide and dexamethasone combination therapy. Deep vein thrombosis (DVT) and pulmonary embolism (PE) have occurred; monitor for signs and symptoms of thromboembolism (shortness of breath, chest pain, or arm or leg swelling) and instruct patients to seek prompt medical attention with development of these symptoms.",
"     </b>",
"     The NCCN multiple myeloma guidelines (v1.2013) recommend anticoagulant prophylaxis when used in combination with dexamethasone. Anticoagulant prophylaxis should be individualized and selected based on the venous thromboembolism risk of the combination treatment regimen, using the safest and easiest to administer (Palumbo, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor flare: Observed in studies of lenalidomide for the treatment of chronic lymphocytic leukemia (CLL) and lymphoma; clinical presentation includes low grade fever, pain, rash, and tender lymph node swelling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Patients with a high tumor burden may be at risk for tumor lysis syndrome; monitor closely; institute appropriate management for hyperuricemia. Tumor lysis syndrome (with fatalities) has been reported with lenalidomide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may experience an increased rate of toxicities due to reduced clearance and increased half-life. Initial dosage adjustments are recommended for moderate-to-severe and dialysis-dependent renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Certain adverse reactions (DVT, pulmonary embolism, atrial fibrillation, renal failure) are more likely in elderly patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: If used in patients between 12-18 years of age, the parent or legal guardian must agree to ensure compliance with the Revlimid REMS&trade; program.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Lenalidomide is an analogue of thalidomide (a human teratogen) and could potentially cause birth defects in humans; do not use during pregnancy (contraindication); avoid pregnancy while taking lenalidomide. Obtain 2 negative pregnancy tests prior to initiation of treatment; 2 forms of contraception (or abstain from heterosexual intercourse) must be used at least 4 weeks prior to, during and for 4 weeks after lenalidomide treatment (and during treatment interruptions). Distribution is restricted; physicians, pharmacies, and patients must be registered with the Revlimid REMS&trade; program.",
"     </b>",
"     Males taking lenalidomide (even those vasectomized) must use a latex or synthetic condom during any sexual contact with women of childbearing potential and for up to 28 days following discontinuation of therapy. Males taking lenalidomide must not donate sperm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Distribution is restricted; physicians, pharmacies, and patients must be registered with the Revlimid REMS&trade; program.",
"     </b>",
"     Lenalidomide should only be prescribed to patients (male and female) who can understand and comply with the conditions of the Revlimid REMS&trade; program.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood donation: Patients should be advised not to donate blood during therapy and for 1 month following completion of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose intolerance: Product may contain lactose; avoid use in patients with Lapp lactase deficiency, glucose-galactose malabsorption, or glucose intolerance.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2407598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexamethasone (Systemic): May enhance the thrombogenic effect of Lenalidomide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Lenalidomide may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2998082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Herb/Nutraceutical: Avoid echinacea (has immunostimulant properties; consider therapy modifications).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2407580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2407581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Lenalidomide is an analogue of thalidomide (a human teratogen) and could potentially cause birth defects in humans; do not use during pregnancy (contraindication); avoid pregnancy while taking lenalidomide. Obtain 2 negative pregnancy tests prior to initiation of treatment; 2 forms of contraception (or abstain from heterosexual intercourse) must be used at least 4 weeks prior to, during, and for 4 weeks after lenalidomide treatment (and during treatment interruptions). Distribution is restricted; physicians, pharmacies, and patients must be registered with the Revlimid REMS&trade; program.",
"     </b>",
"     Animal reproduction studies with lenalidomide in nonhuman primates have demonstrated malformations similar to those observed in humans with thalidomide.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Women of childbearing potential should be treated only if they are able to comply with the conditions of the Revlimid REMS&trade; program. Women of reproductive potential must avoid pregnancy 4 weeks prior to therapy, during therapy, during therapy interruptions, and for &ge;4 weeks after therapy is discontinued. Two forms of effective contraception or total abstinence from heterosexual intercourse must be used by females who are not infertile or who have not had a hysterectomy. A negative pregnancy test (sensitivity of at least 50 mIU/mL) 10-14 days prior to therapy, within 24 hours prior to beginning therapy, weekly during the first 4 weeks, and every 4 weeks (every 2 weeks for women with irregular menstrual cycles) thereafter is required for women of childbearing potential. Lenalidomide must be immediately discontinued for a missed period, abnormal pregnancy test or abnormal menstrual bleeding; refer patient to a reproductive toxicity specialist if pregnancy occurs during treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Lenalidomide is also present in the semen of males. Males (including those vasectomized) should use a latex or synthetic condom during any sexual contact with women of childbearing age during treatment, during treatment interruptions, and for 4 weeks after discontinuation. Male patients should not donate sperm during, and for 4 weeks after treatment, and during therapy interruptions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The parent or legal guardian for patients between 12 and 18 years of age must agree to ensure compliance with the required guidelines. Any suspected fetal exposure should be reported to the FDA via the MedWatch program (1-800-FDA-1088) and to Celgene Corporation (1-888-423-5436).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2407584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2407585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if lenalidomide is excreted in breast milk. Due to the potential for serious adverse reactions in the infant, a decision should be made to discontinue nursing or discontinue treatment. Use in breast-feeding women is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Revlimid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (28): $13061.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (28): $13061.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (28): $13285.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (21): $10004.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (21): $10103.09",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2407617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (MDS: weekly for first 8 weeks; multiple myeloma: every 2 weeks for the first 3 months), then monthly thereafter; serum creatinine, liver function tests, thyroid function tests (TSH at baseline then every 2-3 months during lenalidomide treatment [Hamnvik, 2011]); ECG when clinically indicated; monitor for signs and symptoms of thromboembolism or tumor lysis syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Women of childbearing potential: Pregnancy test 10-14 days",
"     <b>",
"      and",
"     </b>",
"     24 hours prior to initiating therapy, weekly during the first 4 weeks of treatment, then every 2-4 weeks through 4 weeks after therapy discontinued",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ladevina (AR);",
"     </li>",
"     <li>",
"      Lenangio (IN);",
"     </li>",
"     <li>",
"      Revlimid (AT, AU, BE, CH, CN, CR, CZ, DE, DK, EC, EE, FR, GB, GR, GT, HK, HN, IE, IL, IT, MY, NI, NL, NO, NZ, PA, PE, PH, PT, RU, SE, SG, SV, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2407602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunomodulatory, antiangiogenic, and antineoplastic characteristics via multiple mechanisms. Selectively inhibits secretion of proinflammatory cytokines (potent inhibitor of tumor necrosis factor-alpha secretion); enhances cell-mediated immunity by stimulating proliferation of anti-CD3 stimulated T cells (resulting in increased IL-2 and interferon gamma secretion); inhibits trophic signals to angiogenic factors in cells. Inhibits the growth of myeloma cells by inducing cell cycle arrest and cell death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2407604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 3-5 hours; Moderate-to-severe renal impairment: Increased threefold; Hemodialysis patients: Increased ~4.5-fold",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time, to peak, plasma: MDS or myeloma patients: 0.5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~82%; as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodialysis effect: ~40% of a dose is removed in a single dialysis session",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Attal M, Lauwers-Cances V, Marit G, et al, &ldquo;Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(19):1782-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/22571202/pubmed\" id=\"22571202\" target=\"_blank\">",
"        22571202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barlogie B, Shaughnessy J, Tricot G, et al, &ldquo;Treatment of Multiple Myeloma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(1):20-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/12969978/pubmed\" id=\"12969978\" target=\"_blank\">",
"        12969978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chanan-Khan A, Miller KC, Musial L, et al, &ldquo;Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(34):5343-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/17088571/pubmed\" id=\"17088571\" target=\"_blank\">",
"        17088571",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen N, Kasserra C, Reyes J, et al, &ldquo;Single-dose Pharmacokinetics of Lenalidomide in Healthy Volunteers: Dose Proportionality, Food Effect, and Racial Sensitivity,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2012, 70(5):717-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/22955172/pubmed\" id=\"22955172\" target=\"_blank\">",
"        22955172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen N, Lau H, Kong L, et al, &ldquo;Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007, 47(12):1466-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/17954615/pubmed\" id=\"17954615\" target=\"_blank\">",
"        17954615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dimopoulos M, Alegre A, Stadtmauer EA et al, &ldquo;The Efficacy and Safety of Lenalidomide Plus Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2010, 116(16):3807-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/20564094/pubmed\" id=\"20564094\" target=\"_blank\">",
"        20564094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dimopoulos MA, Anagnostopoulos A, and Weber D, &ldquo;Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(23):4444-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/14645435/pubmed\" id=\"14645435\" target=\"_blank\">",
"        14645435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dimopoulos MA, Richardson PG, Brandenburg N, et al, &ldquo;A Review of Second Primary Malignancy in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 9(12):2764-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/22323483/pubmed\" id=\"22323483\" target=\"_blank\">",
"        22323483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dimopoulos M, Spencer A, Attal M, et al, &ldquo;Lenalidomide Plus Dexamethasone for Relapsed or Refractory Multiple Myeloma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(21):2123-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/18032762/pubmed\" id=\"18032762\" target=\"_blank\">",
"        18032762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dispenzieri A, Lacy MQ, Zeldenrust SR, et al, &ldquo;The Activity of Lenalidomide With or Without Dexamethasone in Patients With Primary Systemic Amyloidosis,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(2):465-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/17008538/pubmed\" id=\"17008538\" target=\"_blank\">",
"        17008538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Faderl S and Kantarjian HM, &ldquo;Novel Therapies for Myelodysplastic Syndromes,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 101(2): 226-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fenaux P, Giagounidis A, Selleslag D, et al, &ldquo;A Randomized Phase 3 Study of Lenalidomide versus Placebo in RBC Transfusion-Dependent Patients With Low-/Intermediate-1-Risk Myelodysplastic Syndromes With del5q,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(14):3765-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/21753188/pubmed\" id=\"21753188\" target=\"_blank\">",
"        21753188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrajoli A, Lee BN, Schlette EJ, et al, &ldquo;Lenalidomide Induces Complete and Partial Remissions in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(11): 5291-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/18334676/pubmed\" id=\"18334676\" target=\"_blank\">",
"        18334676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giagounidis AA, Germing U, Strupp C, et al, &ldquo;Prognosis of Patients with del(5q) MDS and Complex Karotype and the Possible Role of Lenalidomide in this Patient Subgroup,&rdquo;",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 2005, 84(9):569-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/15891887/pubmed\" id=\"15891887\" target=\"_blank\">",
"        15891887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giagoundis A, Raza A, List AF, et al, &ldquo;Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):1704 [abstract 1704 from 2011 ASH Annual Meeting]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Habermann TM, Lossos IS, Justice G, et al, &ldquo;Lenalidomide Oral Monotherapy Produces a High Response Rate in Patients With Relapsed or Refractory Mantle Cell Lymphoma,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2009, 145(3):344-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/19245430/pubmed\" id=\"19245430\" target=\"_blank\">",
"        19245430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar S, Flinn I, Richardson PG, et al, &ldquo;Randomized, Multicenter, Phase 2 Study (EVOLUTION) of Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Previously Untreated Multiple Myeloma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(19):4375-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/22422823/pubmed\" id=\"22422823\" target=\"_blank\">",
"        22422823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kyle RA and Rajkumar SV, &ldquo;Multiple Myeloma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(18):1860-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/15509819/pubmed\" id=\"15509819\" target=\"_blank\">",
"        15509819",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larocca A, Cavallo F, Bringhen S, et al, &ldquo;Aspirin or Enoxaparin Thromboprophylaxis for Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(4):933-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/21835953/pubmed\" id=\"21835953\" target=\"_blank\">",
"        21835953",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      List A, Dewald G, Bennett J, et al, &ldquo;Lenalidomide in Myelodysplastic Syndrome With Chromosome 5q Deletion,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(14):1456-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/17021321/pubmed\" id=\"17021321\" target=\"_blank\">",
"        17021321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      List A, Kurtin S, Roe DJ, et al, &ldquo;Efficacy of Lenalidomide in Myelodysplastic Syndromes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(6):549-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/15703420/pubmed\" id=\"15703420\" target=\"_blank\">",
"        15703420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCarthy PL, Owzar K, Hofmeister CC, et al, &ldquo;Lenalidomide After Stem-Cell Transplantation for Multiple Myeloma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(19):1770-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/22571201/pubmed\" id=\"22571201\" target=\"_blank\">",
"        22571201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moreau P, Jaccard A, Benboubker L, et al, &ldquo;Lenalidomide in Combination With Melphalan and Dexamethasone in Patients With Newly Diagnosed AL Amyloidosis: A Multicenter Phase 1/2 Dose-Escalation Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(23):4777-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/20724537/pubmed\" id=\"20724537\" target=\"_blank\">",
"        20724537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Multiple Myeloma,&rdquo; Version 1.2013. Available at file://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oehrlein K, Langer C, Sturm I, et al, &ldquo;Successful Treatment of Patients With Multiple Myeloma and Impaired Renal Function With Lenalidomide: Results of 4 German Centers,&rdquo;",
"      <i>",
"       Clin Lymphoma Myeloma Leuk",
"      </i>",
"      , 2012, 12(3):191-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/22341857/pubmed\" id=\"22341857\" target=\"_blank\">",
"        22341857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Gay F, Falco P, et al, &ldquo;Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(5):800-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/20048187/pubmed\" id=\"20048187\" target=\"_blank\">",
"        20048187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Hajek R, Delforge M, et al, &ldquo;Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(19):1759-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/22571200/pubmed\" id=\"22571200\" target=\"_blank\">",
"        22571200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Larocca A, Zweegman S, et al, &ldquo;Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):996 [abstract 996 from 2011 ASH Annual Meeting]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Rajkumar SV, Dimopoulos MA, et al, &ldquo;Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2008, 22(2):414-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/18094721/pubmed\" id=\"18094721\" target=\"_blank\">",
"        18094721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rajkumar SV, Hayman SR, Lacy MQ, et al, &ldquo;Combination Therapy With Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(13):4050-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/16118317/pubmed\" id=\"16118317\" target=\"_blank\">",
"        16118317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raza A, Reeves JA, Feldman JA, et al, &ldquo;Phase 2 Study of Lenalidomide in Transfusion-Dependent, Low-Risk, and Intermediate-1 Risk Myelodysplastic Syndromes With Karyotypes Other than Deletion 5q,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(1):86-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/17893227/pubmed\" id=\"17893227\" target=\"_blank\">",
"        17893227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Schlossman RL, Weller E, et al, &ldquo;Immunomodulatory Drug CC-5013 Overcomes Drug Resistance and Is Well Tolerated in Patients With Relapsed Multiple Myeloma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 100(9):3063-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/12384400/pubmed\" id=\"12384400\" target=\"_blank\">",
"        12384400",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Weller E, Lonial S, et al, &ldquo;Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(5):679-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/20385792/pubmed\" id=\"20385792\" target=\"_blank\">",
"        20385792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanchorawala V, Wright DG, Rosenzweig M, et al, &ldquo;Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Results of a Phase 2 Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(2):492-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/16960148/pubmed\" id=\"16960148\" target=\"_blank\">",
"        16960148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teo SK, &ldquo;Properties of Thalidomide and Its Analogues: Implications for Anticancer Therapy&rdquo;",
"      <i>",
"       AAPSJ",
"      </i>",
"      , 2005, 7(1):e14-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/16146335/pubmed\" id=\"16146335\" target=\"_blank\">",
"        16146335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Usmani S, Sexton R, Hoering A, et al, &ldquo;Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide versus Thalidomide in Maintenance Phases,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):823 [abstract 823 from 2011 ASH Annual Meeting]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weber DM, Chen C, Niesvizky R, et al, &ldquo;Lenalidomide Plus Dexamethasone for Relapsed Multiple Myeloma in North America,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(21):2133-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/18032763/pubmed\" id=\"18032763\" target=\"_blank\">",
"        18032763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiernik PH, Lossos IS, Tuscano JM, et al, &ldquo;Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(30):4952-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/25/16793/abstract-text/18606983/pubmed\" id=\"18606983\" target=\"_blank\">",
"        18606983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9822 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16793=[""].join("\n");
var outline_f16_25_16793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709009\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407571\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027963\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407576\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407611\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407612\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407613\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160282\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407614\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407623\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407574\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234038\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874837\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407615\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407578\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407579\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401642\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407591\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407586\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407587\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299581\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407598\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2998082\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407580\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407581\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407584\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407585\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322927\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407617\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539966\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407602\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407604\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9822\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9822|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/39/11894?source=related_link\">",
"      Lenalidomide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_25_16794="Preconception evaluation and counseling";
var content_f16_25_16794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preconception evaluation and counseling",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/25/16794/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/25/16794/contributors\">",
"     Joyce A Sackey, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/25/16794/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/25/16794/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/25/16794/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/25/16794/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/25/16794/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preconception care refers to interventions that aim to identify and modify biomedical, behavioral, and social risks to a woman's health or pregnancy outcome through prevention and management [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/1\">",
"     1",
"    </a>",
"    ]. Preconception evaluation and counseling provide an opportunity to inform women about",
"    <span class=\"nowrap\">",
"     fertility/pregnancy",
"    </span>",
"    issues, identify some of the risks of pregnancy for the mother and fetus, educate them about these risks, and institute appropriate interventions, when possible, before conception [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimizing the health of the mother",
"    <strong>",
"     before",
"    </strong>",
"    conception is important for improving pregnancy outcome. This is particularly true for certain populations of women, such as those with medical disorders (eg, diabetes mellitus, phenylketonuria), nutritional deficiencies (eg, folate), and exposure to toxins or teratogens (eg, cigarettes, alcohol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    ), in whom preconception care can reduce neonatal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. In particular, preconception care is more important than prenatal care for prevention of congenital anomalies since as many as 30 percent of pregnant women begin traditional prenatal care in the second trimester (&gt;13 weeks of gestation), which is after the period of maximal organogenesis (between 3 and 10 weeks of gestation) (",
"    <a class=\"graphic graphic_figure graphicRef56642 \" href=\"UTD.htm?22/46/23272\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The Preconception Care Work Group of the Centers for Disease Control recommended that preconception care be an essential part of primary and preventive care, rather than an isolated visit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. Potential opportunities for preconception counseling occur during many nonemergency health care encounters, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Premarital examination and testing",
"     </li>",
"     <li>",
"      Contraception counseling",
"     </li>",
"     <li>",
"      Evaluation for sexually transmitted disease or vaginal infection",
"     </li>",
"     <li>",
"      After a negative pregnancy test",
"     </li>",
"     <li>",
"      Anytime a woman of childbearing age presents for a periodic health examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BARRIERS TO PRECONCEPTION COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of barriers to preconception care and intervention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unplanned pregnancy",
"     </li>",
"     <li>",
"      Risk factors for adverse outcome that cannot be modified (eg, maternal age or genetic history)",
"     </li>",
"     <li>",
"      Financial issues (eg, lack of health insurance, nonreimbursable services)",
"     </li>",
"     <li>",
"      Inadequate training of health care providers and long waiting times for appointments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Unplanned pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently shown that planned pregnancies generally have better outcomes than unplanned ones [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/1\">",
"     1",
"    </a>",
"    ]. However, almost 50 percent of pregnancies in the United States are unintended [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/9\">",
"     9",
"    </a>",
"    ]. In one study, for example, 40 percent of the mothers surveyed three to six months after delivery reported that their pregnancy was unplanned [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/10\">",
"     10",
"    </a>",
"    ]. One-half of women who planned their pregnancy and two-thirds of the mothers with unintended pregnancies had one or more indications for preconception counseling (smoking within three months of pregnancy, drinking three or more drinks at one time within three months of pregnancy, low body mass index, or delayed initiation of prenatal care [after the first trimester]).",
"   </p>",
"   <p>",
"    These findings suggest that preconception counseling should be provided to all women of childbearing age, regardless of their immediate pregnancy plans [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Moreover, a preconception program in a family planning clinic has been shown to be a useful approach for promoting intentionally planned pregnancy in low-income women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Financial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preconception counseling may not be fully reimbursed by third-party payers. Many insurers currently do not provide coverage for screening tests as part of preconception counseling, although these same tests are covered when performed in early pregnancy. Furthermore, a number of low income women have multiple risk factors for adverse pregnancy outcome and are less knowledgeable about pregnancy and health. These women often do not have any health insurance and, therefore, may be reluctant to seek preconception care. Difficulties with child care and transportation are also barriers to access services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Provider factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women's health care providers should be trained to perform adequate assessment of pregnancy risks, offer appropriate recommendations for intervention, and provide basic patient education [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Situations beyond the provider's expertise should prompt consideration of referral to genetic counseling or specialty care.",
"   </p>",
"   <p>",
"    Lack of coordination among providers of women's health services can be a barrier to optimum care. Healthcare systems that develop strategies to provide more culturally competent care, more timely appointments, and assistance with insurance applications may be able to increase the number of women seeking early prenatal services [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMPONENTS OF THE PRECONCEPTION EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three components of preconception counseling are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of risks related to pregnancy",
"     </li>",
"     <li>",
"      Patient education regarding pregnancy risks, management options, and reproductive alternatives",
"     </li>",
"     <li>",
"      Initiation of interventions, when possible, to provide optimum pregnancy outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is limited evidence as to the best means for delivering preconception care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/1,13,18,19\">",
"     1,13,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key task in identifying risks to the woman and her pregnancy is to obtain a thorough history. Several paper and computerized questionnaires and record forms are commercially available for this purpose (",
"    <a class=\"graphic graphic_form graphicRef55575 \" href=\"UTD.htm?29/54/30574\">",
"     form 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/19\">",
"     19",
"    </a>",
"    ]. Patient education and medical interventions can subsequently be initiated using this database.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;It makes intuitive sense that there should be a benefit to identifying and treating medical conditions, including mental health issues, prior to pregnancy. However, data from clinical trials demonstrating improved outcome with preconception intervention exists for only a handful of conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/4,20-25\">",
"     4,20-25",
"    </a>",
"    ]. These disorders are primarily metabolic, such as diabetes mellitus or phenylketonuria, or autoimmune, such as systemic lupus erythematosus. In addition, sometimes a medication can be stopped (eg, valproic acid), should be stopped (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    ), or changed to one that is safer for the pregnant woman or fetus (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"     \"Pregnancy in women with systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=see_link\">",
"     \"Overview of phenylketonuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complete medical history is useful for discussing how pregnancy can affect maternal medical conditions and the effect of a medical disorder on the fetus and pregnancy (",
"    <a class=\"graphic graphic_table graphicRef69716 \" href=\"UTD.htm?31/31/32253\">",
"     table 1",
"    </a>",
"    ). The patient's medications (including over-the-counter and prescription drugs) should be discussed to determine whether potentially teratogenic substances are being used. A partial list of common teratogens is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef73369 \" href=\"UTD.htm?4/58/5024\">",
"     table 2",
"    </a>",
"    ). It is especially important to elicit exposure to dietary supplements (eg, herbal supplements), as patients may not perceive them as medications that can be harmful to the fetus. A dietary evaluation also should include an assessment of body mass index and eating habits (eg, food restrictions). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideally, any woman with a history of anaphylaxis in the past should be referred to an allergy specialist for evaluation PRIOR to pregnancy. This is particularly important for women who experienced anaphylaxis in association with a previous medical or dental procedure, as similar medications may be needed during labor and delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7610?source=see_link\">",
"     \"Anaphylaxis in pregnant and breastfeeding women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced maternal age is associated with increased pregnancy risks that include infertility, fetal aneuploidy, gestational diabetes, preeclampsia, and stillbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/26\">",
"     26",
"    </a>",
"    ]. Women should be aware of these risks and the consequences of delaying conception until they are over 35 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30567?source=see_link\">",
"     \"Effect of advanced paternal age on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Reproductive history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gynecologic and obstetric histories are important for identifying factors that may contribute to infertility or complications in a future pregnancy (",
"    <a class=\"graphic graphic_table graphicRef78008 \" href=\"UTD.htm?33/21/34139\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/27\">",
"     27",
"    </a>",
"    ]. Uterine anomalies, as an example, can be associated with recurrent pregnancy wastage or preterm birth. The recurrence risk of an adverse outcome (eg, miscarriage, preterm birth, intrauterine growth restriction, preeclampsia, congenital anomaly, perinatal death) should be discussed with women who have a history of pregnancy complications. In some cases, interventions to reduce or eliminate the risk of recurrence are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the patient's family history helps to identify genetic risks to the fetus and maternal medical risks that may not have been appreciated. As an example, a woman may not be aware that a family history of thromboembolic disease can put her at risk for thromboembolic and pregnancy complications. The components of a genetic history are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef78915 \" href=\"UTD.htm?24/30/25068\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Substance use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to tobacco, alcohol, and illicit drugs can be harmful to both the mother and fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. Thus, it is important to screen women for use of these substances [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"     \"Smoking and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"     \"Alcohol intake and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link&amp;anchor=H98182254#H98182254\">",
"     \"Screening for unhealthy use of alcohol and other drugs\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of tobacco in pregnancy has been associated with several adverse outcomes, including miscarriage, prematurity, and low birth weight [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A spectrum of birth defects related to alcohol intake during pregnancy may occur, ranging from subtle growth retardation and neurobehavioral effects with moderate alcohol intake, to the fetal alcohol syndrome with heavy use. It has been estimated that more than half of women of childbearing age who do not use contraception (and thus are at risk of getting pregnant) consume alcohol, with approximately 2 percent engaging in binge or frequent alcohol use [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/33\">",
"       33",
"      </a>",
"      ]. It is therefore important to elicit any history of alcohol consumption when evaluating a woman of childbearing age.",
"     </li>",
"     <li>",
"      Illicit drugs have variable effects on pregnancy outcome that may be related to social disturbances in the mother, in addition to effects of the drugs themselves [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial stress, mental health, and financial issues should be identified and appropriate interventions taken with the help of a community resource specialist. It is particularly important to screen for the presence of domestic violence, lack of social support, and barriers to prenatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link\">",
"     \"Intimate partner violence: Diagnosis and screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal psychiatric illness should be identified and treated, as appropriate, because untreated or inadequately treated disease will result in maternal suffering and could lead to a variety of consequences, such as poor compliance with prenatal care, poor nutrition, substance abuse, or disturbed relationships between the mother and her infant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/36\">",
"     36",
"    </a>",
"    ]. Ideally, the patient should wait until she has become euthymic, which may take 6 to 12 months, before she attempts to conceive [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who have been on medication and have mild or no symptoms for six or more months may be considered for medication taper and discontinuation (eg, decrease medication by 25 percent every one to two weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/37\">",
"     37",
"    </a>",
"    ]. Some women may benefit from psychotherapy. Discontinuation of pharmacotherapy is generally not advised for women with a history of severe recurrent depressive disorders, psychosis, bipolar illness, psychiatric comorbidity requiring pharmacotherapy, or a history of suicidal ideation.",
"   </p>",
"   <p>",
"    Drugs used to treat psychiatric disease can affect the fetus and neonate; this topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Environmental exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions about the woman's work, hobbies, pets, and home environment can identify potentially toxic exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/38\">",
"     38",
"    </a>",
"    ]. Examples of such hazards include organic solvents used in manufacturing processes, toxoplasmosis risk from changing cat litter boxes or eating under-cooked meat, mercury from fish consumption, and lead used in arts and crafts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/39\">",
"     39",
"    </a>",
"    ]. There is no convincing evidence that exposure to common sources of electromagnetic field radiation, such as computer monitors, electric blankets, heated water beds, and microwave ovens, is harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Occupational Safety and Health Administration (OSHA) sets and enforces standards requiring employers to provide a workplace free from recognized hazards likely to cause serious physical harm. This information should be available at the patient's workplace. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=see_link\">",
"     \"Overview of occupational and environmental health\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=see_link\">",
"     \"Occupational and environmental risks to reproduction in females\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Caffeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have reported a association between caffeine intake and some adverse pregnancy outcomes. Major limitations of these studies is their inability to adjust for confounders or accurately measure caffeine intake, which depends upon the size of the cup, brand of coffee, and brewing method. Given the limitations and inconsistencies of available data, it may be prudent for women who are attempting to conceive or who are pregnant to limit caffeine consumption to less than 200 mg per day to potentially reduce their risk of possible adverse reproductive effects.",
"   </p>",
"   <p>",
"    The effects of caffeine on pregnancy outcomes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20026?source=see_link\">",
"     \"The effects of caffeine on reproductive outcomes in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal obesity has been linked to subfertility, having a child with a congenital anomaly, and several other pregnancy complications (gestational diabetes, preeclampsia, cesarean delivery, macrosomia, difficult delivery, and",
"    <span class=\"nowrap\">",
"     stillbirth/early",
"    </span>",
"    neonatal death). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link&amp;anchor=H9#H9\">",
"     \"Optimizing natural fertility in couples planning pregnancy\", section on 'Body mass index'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although weight loss to reduce pregnancy risks has not been studied (except in women with polycystic ovary syndrome and after bariatric surgery), the clear overall health benefits of achieving a normal body mass index have been well described. In 2009, the Institute of Medicine (IOM) published new guidelines for weight gain during pregnancy and recommended that women planning pregnancy achieve their normal body mass index (BMI) before they conceive [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/41\">",
"     41",
"    </a>",
"    ]. Specifically, the IOM recommended that \"health care providers inform women of the importance of conceiving at a normal BMI and that all those who provide health care or related services to women of childbearing age include preconceptional counseling in their care. Also \"those who provide prenatal care to women should offer them counseling, such as guidance on dietary intake and physical activity, that is tailored to their life circumstances.\" (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link\">",
"     \"Weight gain and loss in pregnancy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination in the preconception evaluation is the same as for the routine periodic health evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .) Important aspects to highlight include examination of the thyroid gland, breasts, heart, skin, and a pelvic examination. The pelvic examination should include cervical cancer screening and, for patients in whom it is indicated, screening for gonorrhea and chlamydia (see below). Dental caries and other oral diseases (eg, periodontal disease) also are common and may be associated with pregnancy complications, such as preterm delivery; thus, referral to a dentist is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=see_link&amp;anchor=H21#H21\">",
"     \"Prevention of spontaneous preterm birth\", section on 'Treatment of periodontal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory assessment/screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of laboratory tests depends upon the general guidelines recommended for all pregnant women and the individual's personal medical history. Routine laboratory examination includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rubella titer",
"     </li>",
"     <li>",
"      Varicella titer, in women with a negative history of varicella",
"     </li>",
"     <li>",
"      Hepatitis B surface antigen",
"     </li>",
"     <li>",
"      Complete blood count with red cell indices (MCV &lt;80 may indicate hemoglobinopathy). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24999?source=see_link\">",
"       \"Prenatal testing for the hemoglobinopathies and thalassemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HIV counseling and testing, with patient consent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"       \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these tests, further testing may be considered in those patients with specific clinical indications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma glucose concentration for patients at increased risk of diabetes (eg, history of gestational diabetes mellitus, macrosomia [prior baby with birth weight greater than nine pounds], overweight or obese [body mass index &ge;25",
"      <span class=\"nowrap\">",
"       kg/m2],",
"      </span>",
"      or family history of diabetes in a first degree relative) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/42\">",
"       42",
"      </a>",
"      ]. The interpretation of fasting and random glucose measurements is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link&amp;anchor=H2#H2\">",
"       \"Screening for diabetes mellitus\", section on 'Type 1 diabetes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link&amp;anchor=H3#H3\">",
"       \"Screening for diabetes mellitus\", section on 'Type 2 diabetes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mantoux test for tuberculosis in high risk populations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"       \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      .) Patients with a positive Mantoux test should have a chest radiograph to exclude active tuberculin disease and appropriate treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=see_link\">",
"       \"Tuberculosis in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatitis C antibody in high risk populations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"       \"Epidemiology and transmission of hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Toxoplasmosis titer in patients with occupational exposure, pet cats, or high risk eating habits. Patients with a negative toxoplasmosis titer should be counseled to avoid changing the cat litter, forgo eating under-cooked meat, wear gloves when gardening, and frequently wash food, hands, and food preparation areas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"       \"Toxoplasmosis and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cytomegalovirus titer in women who work in child care facilities or dialysis units or have children in day care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"       \"Cytomegalovirus infection in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening for sexually transmitted diseases including gonorrhea, chlamydia, and syphilis. Some experts have argued for routine screening of all sexually active women under age 25 for chlamydia since infections with this organism are highly prevalent and to a large extent asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/43\">",
"       43",
"      </a>",
"      ]. While the cost-effectiveness of such an approach has not been fully demonstrated, a case can be made for chlamydia screening during the preconception evaluation in women with risk factors (eg, new or multiple partners, history of sexually transmitted diseases, inconsistent condom use). Screening for gonorrhea and syphilis should similarly be pursued in women with risk factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"       \"Screening for sexually transmitted infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=see_link\">",
"       \"Screening for Chlamydia trachomatis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38217?source=see_link\">",
"       \"Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic carrier testing based upon a family history of heritable disease or ethnic origin (eg, testing for cystic fibrosis gene mutations, hemoglobin electrophoresis, hexosaminidase A level) (",
"      <a class=\"graphic graphic_table graphicRef78915 \" href=\"UTD.htm?24/30/25068\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/44\">",
"       44",
"      </a>",
"      ]. (See individual topic reviews). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=see_link\">",
"       \"Prenatal screening for genetic disease in the Ashkenazi Jewish population\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24999?source=see_link\">",
"       \"Prenatal testing for the hemoglobinopathies and thalassemias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22503?source=see_link\">",
"       \"Cystic fibrosis: Prenatal genetic screening\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum phenylalanine level if maternal phenylketonuria is known or suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=see_link\">",
"       \"Overview of phenylketonuria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lead level, if the patient is at high risk of lead exposure or an increased lead level (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H939359#H939359\">",
"       \"Initial prenatal assessment and patient education\", section on 'Lead level screening'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"       \"Adult lead poisoning\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Exposure to ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above, women who undergo periodic screening tests (eg, mammogram, dental films, chest radiographs) involving ionizing radiation should schedule these tests prior to attempts at conception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the pregnancy risk assessment is performed, preconception interventions are directed at preparing and educating the patient, providing optimum therapy of medical disorders, and referral for specialized care, when appropriate. Ideally, the patient and her provider will create a reproductive health plan, which will be reviewed and revised, as needed, at each visit. No randomized trials have studied the effectiveness of this approach. However, there is good evidence of efficacy of specific interventions, such as preconception glycemic control in diabetics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation, avoidance of teratogens, and following a low phenylalanine diet in women with phenylketonuria (see individual topic reviews) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/4,25,45\">",
"     4,25,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If pregnancy avoidance is desired, then contraceptive options should be discussed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Maternal medical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of maternal medical conditions, including changes in medications to incorporate medications known to be safer in pregnancy, is an important step. Some common or serious medical conditions that impact or are impacted by pregnancy are discussed briefly below, additional disorders are reviewed separately. (See individual topic reviews on medical disorders, section on pregnancy).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperglycemia is probably the most important determinant of increased fetal risk in pregnant women with diabetes. This conclusion is supported by repeated observations that normalizing blood glucose concentrations before and early in pregnancy can reduce the risk of miscarriage and congenital malformations to nearly that of nondiabetic women. The woman with diabetes who is on an oral anti-hyperglycemic agent may be switched to insulin, and consideration should generally be given to referring all women with pregestational diabetes to a diabetologist to achieve optimal glycemic control. The use of oral anti-hyperglycemic agents during pregnancy is controversial, but is gaining acceptance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=see_link\">",
"       \"Medical management of type 1 and type 2 diabetes mellitus in pregnant women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"       \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"       \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For a patient with hypertension, the goal should be to control blood pressure prior to conception. Certain agents, such as ACE inhibitors, should be avoided in pregnancy, as their use at any stage of pregnancy is associated with adverse effects on the fetus [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/46\">",
"       46",
"      </a>",
"      ]. Patients who are on any of these agents should be advised to switch to agents whose safety in pregnancy is established (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ). Women who have long-standing or poorly controlled hypertension should be evaluated for end-organ effects (eg, ventricular hypertrophy, retinopathy, renal insufficiency) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"       \"Management of hypertension in pregnant and postpartum women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link\">",
"       \"Overview of hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asthma should be under good control prior to attempting conception. If necessary, the use of steroids (inhaled and systemic) in pregnancy is generally safe, particularly when compared with the risk of maternal acid base disturbance and hypoxemia to the fetus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=see_link\">",
"       \"Physiology and clinical course of asthma in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=see_link\">",
"       \"Management of asthma during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with thyroid disease require close monitoring of thyroid function tests during pregnancy as the dose of medication to treat thyroid dysfunction typically needs to be adjusted during pregnancy. Both hyper- and hypo-thyroidism can affect pregnancy outcome. In particular, neuropsychological impairment in offspring may occur even in women with subclinical hypothyroidism. There is insufficient evidence to recommend for or against routine screening of thyroid function in women planning to become pregnant, but women with symptoms suggestive of thyroid disease should be tested. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of thyroid disease in pregnancy\", section on 'Screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with a history of seizures and women taking antiepileptic drugs should be referred to a maternal-fetal medicine specialist for a thorough discussion of risks of pregnancy for mother and fetus, possible adjustments in their drug regimen, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation. They should also discuss these issues with their neurologist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=see_link\">",
"       \"Management of epilepsy and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy can pose additional risks to women with cardiovascular disease (congenital or acquired); a baseline cardiac assessment should be performed and potential pregnancy risks should be discussed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"       \"Acquired heart disease and pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"       \"Pregnancy in women with congenital heart disease: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prognosis for both mother and child is best when systemic lupus erythematosus has been quiescent for at least six months prior to the pregnancy, and the patient's underlying renal function is stable and normal or near normal. Maternal medications may need to be changed because of potential risks to the fetus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"       \"Pregnancy in women with systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with inherited thrombophilias are at higher risk of thromboembolic complications during pregnancy because of pregnancy-associated changes in several coagulation factors; in some cases, they are at increased risk of adverse pregnancy outcome, as well. Indications for, and management of, anticoagulation should be addressed with a thrombosis specialist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"       \"Inherited thrombophilias in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Heritable diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those with a positive history for a heritable disease, referral to a specialist in genetic counseling is usually required to discuss carrier testing, the risk of genetic disease in the fetus, options regarding prenatal diagnosis and intervention, and the natural course of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=see_link\">",
"     \"Basic principles of genetic counseling for the obstetrical provider\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cessation of substance use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation and reduction during pregnancy improves pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/29\">",
"     29",
"    </a>",
"    ]. Women who are smokers should be counseled on the benefits of smoking cessation and offered resources to help them quit smoking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"     \"Smoking and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data to establish a safe threshold for alcohol consumption during pregnancy, thus the safest course of action is to abstain entirely [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"     \"Alcohol intake and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who use illicit drugs should be strongly advised of the risks of this behavior and referred to cessation programs in their area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Depression and psychotropic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with active symptoms of depression should be treated, if necessary, with drug therapy. The risks of fetal exposure to medications (eg, neonatal behavioral syndrome) must be balanced against the risks of untreated depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=see_link\">",
"     \"Depression in pregnant women: Clinical features and consequences\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Nutrition and supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nutritionist may be consulted to evaluate restricted diets or to offer advice on eating a well-balanced, healthy diet. A systematic review concluded that provision of preconceptional nutritional counseling improved pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, the fetal environment appears to affect subsequent infant and childhood development [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], and appears to have permanent effects on adult health (Barker hypothesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Thus, dietary changes that optimize fetal growth and development may have health benefits across an individual's lifecycle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"     \"Nutrition in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Megavitamins, non-essential dietary supplements, and herbal preparations should be discontinued, given that the risk to the fetus from such substances has generally not been evaluated. Megadoses of vitamin A taken during early pregnancy have been associated with birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Multivitamin preparations containing more than 5000 international units of vitamin A should be avoided (increased risk of teratogenesis at &gt;10,000 international",
"    <span class=\"nowrap\">",
"     units/day).",
"    </span>",
"   </p>",
"   <p>",
"    All women planning pregnancy or capable of becoming pregnant should be counseled to take a daily multivitamin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (400 to 800 mcg) to reduce the risk of neural tube defects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/56-58\">",
"     56-58",
"    </a>",
"    ], as well as other congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/59\">",
"     59",
"    </a>",
"    ] and possibly abruption [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The neural tube closes between 18 and 26 days after conception so folic acid supplementation after the diagnosis of pregnancy is usually too late to reduce the risk of neural tube defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link\">",
"     \"Folic acid for prevention of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    antagonists increase the risk of neural-tube defects, and also may increase the risk of other congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/62\">",
"     62",
"    </a>",
"    ] and placenta-mediated adverse pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/63\">",
"     63",
"    </a>",
"    ]. There is evidence that suggests folic acid-fortified multivitamins reduce the occurrence of these other congenital anomalies. A systematic review that included 41 studies reported that use of multivitamin supplements was associated with a significantly decreased risk of [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular defects (case control studies OR 0.78, 95% CI 0.67&ndash;0.92; cohort and randomized controlled studies OR 0.61, 95% CI 0.40&ndash;0.92)",
"     </li>",
"     <li>",
"      Limb defects (case control studies OR 0.48, 95% CI 0.30&ndash;0.76; cohort and randomized controlled studies OR 0.57, 95% CI 0.38&ndash;0.85)",
"     </li>",
"     <li>",
"      Cleft lip with or without cleft palate (case control studies OR 0.63, 95% CI 0.54&ndash;0.73; cohort and randomized controlled studies OR 0.58, 95% CI 0.28&ndash;1.19)",
"     </li>",
"     <li>",
"      Urinary tract anomalies (case control studies OR 0.48, 95% CI 0.30&ndash;0.76, cohort and randomized controlled studies OR 0.68, 95% CI 0.35&ndash;1.31).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study supports the use of multivitamins in women of childbearing potential. Further investigation is needed to determine which vitamins are beneficial, and the optimal dose. The estimated average requirement of vitamin D (prepregnancy, pregnancy, and lactation) is 400 IU (10 micrograms) daily (recommended daily allowance 600 IU [15 micrograms]) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/58,64\">",
"     58,64",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=see_link&amp;anchor=H9#H9\">",
"     \"Calcium physiology in pregnancy\", section on 'Vitamin D'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Women with phenylketonuria (PKU) and high blood phenylalanine levels are at risk for having a baby with intellectual disability and congenital heart disease. Health care providers should advise affected women of childbearing age to either stay on a PKU diet or plan their pregnancies to occur after they have reinstituted such a diet [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/22,65\">",
"     22,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=see_link\">",
"     \"Overview of phenylketonuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The quantity and type of fish consumed should also be regulated and certain types of fish should be avoided during pregnancy and the preconception period due to concerns about possible teratogenic effects from environmental toxins. Only cooked fish should be eaten. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link&amp;anchor=H22#H22\">",
"     \"Nutrition in pregnancy\", section on 'Fish'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33273?source=see_link\">",
"     \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High caffeine intake should also probably be avoided. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Caffeine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate exercise is not harmful to the healthy pregnant woman or her fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/66\">",
"     66",
"    </a>",
"    ]. Women who exercise regularly prior to pregnancy may continue with their usual level of physical exertion during pregnancy. Initiation of strenuous exercise during pregnancy, on the other hand, should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial prenatal assessment and patient education\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, a woman should be immune to or immunized against infections that place her or her fetus at risk. These diseases vary by country and personal risk factors (eg, pneumococcal vaccine after splenectomy). Nonpregnant women of childbearing age who may become pregnant should receive all clinically indicated immunizations, preferably at least one month prior to conception. In the United States, this means immunity (as a result of immunization or disease) to measles, mumps, rubella, tetanus, diphtheria, poliomyelitis, and varicella. Immunization issues with respect to pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women are at an increased risk of complications related to influenza infection. It is therefore recommended that women who become pregnant during the influenza season receive the influenza vaccine regardless of stage of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vaccination should be offered to a woman with a negative rubella titer and she should be advised to wait one month before attempting conception since this is a live attenuated virus vaccine.",
"     </li>",
"     <li>",
"      Varicella infection during pregnancy can be associated with significant maternal and fetal morbidity and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. Administration of anti-varicella zoster immunoglobulin to the non-immune woman exposed during pregnancy may not always be effective in preventing clinical disease, although it can attenuate the risk to the fetus [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/68\">",
"       68",
"      </a>",
"      ]. Not surprisingly, then, many have suggested screening women prenatally for evidence of prior varicella exposure in an effort to identify those who are varicella susceptible [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/70\">",
"       70",
"      </a>",
"      ]. A history of varicella infection is generally reliable. Women who deny a history of clinical disease should be offered serologic testing; most of these women will have a positive titer due to prior subclinical disease. A strategy of vaccinating those with a negative titer has been found cost effective [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. Women with high risk of exposure, such as health care workers, should definitely be vaccinated [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/73\">",
"       73",
"      </a>",
"      ]. Women who receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      , a life attenuated vaccine, should be advised to avoid pregnancy for one month.",
"     </li>",
"     <li>",
"      Patients at risk for hepatitis B infection (eg, women with multiple sexual partners, household contacts of patients with hepatitis B, healthcare workers) should be offered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"       \"Hepatitis B virus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Precautions against infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some infections are potentially harmful in pregnancy, particularly in the first trimester. Interventions exist to minimize the risk of these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H22#H22\">",
"     \"Initial prenatal assessment and patient education\", section on 'Infection precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women of childbearing age who are HIV positive should all be offered preconception counseling, with specific emphasis on a thorough discussion of the risk of transmission of HIV to the neonate and how the risk can be modified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Insurance coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, Medicaid is the primary mechanism for extending health coverage to low income women who do not have health insurance. Some women may not be aware that they are eligible to receive these services. Local guidelines regarding eligibility and services should be checked as they vary widely from state to state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Other concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional common concerns that may be addressed at this time include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Timing the initial pregnancy and interval between pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?16/25/16794/abstract/75\">",
"       75",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=see_link\">",
"       \"Interpregnancy interval and pregnancy outcome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Concerns about infertility (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"       \"Overview of infertility\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fears concerning pregnancy",
"     </li>",
"     <li>",
"      Work related issues and maternity leave (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20056?source=see_link\">",
"       \"Work and pregnancy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Marital issues",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend women of childbearing age be offered preconception evaluation and counseling (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The goals of preconception care are to identify risks of pregnancy for the mother and fetus, educate the patient about these risks, and institute appropriate interventions, when possible, before conception. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtaining a thorough history will help in identifying risks to the woman and her pregnancy. We suggest using any one of several commercially available paper and computerized questionnaires and record forms designed for this purpose (",
"      <a class=\"graphic graphic_form graphicRef55575 \" href=\"UTD.htm?29/54/30574\">",
"       form 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's medications (including over-the-counter and prescription drugs and herbal supplements) should be reviewed to determine whether potentially teratogenic substances are being used. Medications should be changed, as needed, so that those known to be safer in pregnancy are administered. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Medical conditions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Maternal medical problems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women should be made aware of fertility and pregnancy problems that increase with advancing age. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Couples with a personal or family history of heritable disorders can benefit from referral to a specialist in genetics or provider familiar with the pertinent issues to discuss carrier testing, the risk of genetic disease in the fetus, options regarding prenatal diagnosis, and the natural course of the disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Family history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The woman should be informed that exposure to tobacco, alcohol, illicit drugs, and some environmental exposures can be harmful to both the mother and fetus. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Substance use'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Environmental exposures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pertinent laboratory tests and immunizations should be addressed preconception to allow time for evaluation and intervention, if required. In particular, rubella and varicella immunizations should be up to date as these are live virus vaccines that should not be given to pregnant women. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Laboratory assessment/screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend women be advised to take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplements to reduce the occurrence of neural tube defects (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The optimal dose is unclear, we suggest a multivitamin with 400 to 800",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      of folic acid (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Nutrition and supplements'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/1\">",
"      Johnson K, Posner SF, Biermann J, et al. Recommendations to improve preconception health and health care--United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Preconceptional care. ACOG technical bulletin 205. American College of Obstetricians and Gynecologists, Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/3\">",
"      Platt LD, Koch R, Hanley WB, et al. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. Am J Obstet Gynecol 2000; 182:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/4\">",
"      Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM 2001; 94:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/5\">",
"      Shannon G, Alberg C, Nacul L, Pashayan N. Preconception health care and congenital disorders: mathematical modelling of the impact of a preconception care programme on congenital disorders. BJOG 2013; 120:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/6\">",
"      De-Regil LM, Fern&aacute;ndez-Gaxiola AC, Dowswell T, Pe&ntilde;a-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 2010; :CD007950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/7\">",
"      Atrash H, Jack BW, Johnson K, et al. Where is the \"W\"oman in MCH? Am J Obstet Gynecol 2008; 199:S259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/8\">",
"      Jack BW, Atrash H, Coonrod DV, et al. The clinical content of preconception care: an overview and preparation of this supplement. Am J Obstet Gynecol 2008; 199:S266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/9\">",
"      Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/10\">",
"      Adams MM, Bruce FC, Shulman HB, et al. Pregnancy planning and pre-conception counseling. The PRAMS Working Group. Obstet Gynecol 1993; 82:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/11\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion number 313, September 2005. The importance of preconception care in the continuum of women's health care. Obstet Gynecol 2005; 106:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/12\">",
"      Moos MK, Dunlop AL, Jack BW, et al. Healthier women, healthier reproductive outcomes: recommendations for the routine care of all women of reproductive age. Am J Obstet Gynecol 2008; 199:S280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/13\">",
"      Moos MK, Bangdiwala SI, Meibohm AR, Cefalo RC. The impact of a preconceptional health promotion program on intendedness of pregnancy. Am J Perinatol 1996; 13:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/14\">",
"      Moser R Jr, McCance KL, Smith KR. Results of a national survey of physicians' knowledge and application of prevention capabilities. Am J Prev Med 1991; 7:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/15\">",
"      Conway T, Mason E, Hu TC. Attitudes, knowledge, and skills of internal medicine residents regarding pre-conception care. Acad Med 1994; 69:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/16\">",
"      Conway T, Hu TC, Mason E, Mueller C. Are primary care residents adequately prepared to care for women of reproductive age? Fam Plann Perspect 1995; 27:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/17\">",
"      Beckmann CA, Buford TA, Witt JB. Perceived barriers to prenatal care services. MCN Am J Matern Child Nurs 2000; 25:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/18\">",
"      Jack BW, Culpepper L, Babcock J, et al. Addressing preconception risks identified at the time of a negative pregnancy test. A randomized trial. J Fam Pract 1998; 47:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/19\">",
"      Bernstein PS, Sanghvi T, Merkatz IR. Improving preconception care. J Reprod Med 2000; 45:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/20\">",
"      Cox M, Whittle MJ, Byrne A, et al. Prepregnancy counselling: experience from 1,075 cases. Br J Obstet Gynaecol 1992; 99:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/21\">",
"      Kitzmiller JL, Gavin LA, Gin GD, et al. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA 1991; 265:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/22\">",
"      Waisbren SE, Hanley W, Levy HL, et al. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA 2000; 283:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/23\">",
"      Hayslett JP. The effect of systemic lupus erythematosus on pregnancy and pregnancy outcome. Am J Reprod Immunol 1992; 28:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/24\">",
"      Spronsen FJ, Smit GP, Erwich JJ. Inherited metabolic diseases and pregnancy. BJOG 2005; 112:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/25\">",
"      Korenbrot CC, Steinberg A, Bender C, Newberry S. Preconception care: a systematic review. Matern Child Health J 2002; 6:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/26\">",
"      Leuzzi RA, Scoles KS. Preconception counseling for the primary care physician. Med Clin North Am 1996; 80:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/27\">",
"      Stubblefield PG, Coonrod DV, Reddy UM, et al. The clinical content of preconception care: reproductive history. Am J Obstet Gynecol 2008; 199:S373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/28\">",
"      Shiono PH, Klebanoff MA, Rhoads GG. Smoking and drinking during pregnancy. Their effects on preterm birth. JAMA 1986; 255:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/29\">",
"      Li CQ, Windsor RA, Perkins L, et al. The impact on infant birth weight and gestational age of cotinine-validated smoking reduction during pregnancy. JAMA 1993; 269:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/30\">",
"      Marbury MC, Linn S, Monson R, et al. The association of alcohol consumption with outcome of pregnancy. Am J Public Health 1983; 73:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Alcohol consumption among pregnant and childbearing-aged women--United States, 1991 and 1995. MMWR Morb Mortal Wkly Rep 1997; 46:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/32\">",
"      Miller JM Jr, Boudreaux MC. A study of antenatal cocaine use-chaos in action. Am J Obstet Gynecol 1999; 180:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Alcohol consumption among women who are pregnant or who might become pregnant--United States, 2002. MMWR Morb Mortal Wkly Rep 2004; 53:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/34\">",
"      Floyd RL, Jack BW, Cefalo R, et al. The clinical content of preconception care: alcohol, tobacco, and illicit drug exposures. Am J Obstet Gynecol 2008; 199:S333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/35\">",
"      Klerman LV, Jack BW, Coonrod DV, et al. The clinical content of preconception care: care of psychosocial stressors. Am J Obstet Gynecol 2008; 199:S362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/36\">",
"      Frieder A, Dunlop AL, Culpepper L, Bernstein PS. The clinical content of preconception care: women with psychiatric conditions. Am J Obstet Gynecol 2008; 199:S328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/37\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009; 114:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/38\">",
"      McDiarmid MA, Gardiner PM, Jack BW. The clinical content of preconception care: environmental exposures. Am J Obstet Gynecol 2008; 199:S357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/39\">",
"      Fischbein A, Wallace J, Sassa S, et al. Lead poisoning from art restoration and pottery work: unusual exposure source and household risk. J Environ Pathol Toxicol Oncol 1992; 11:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/40\">",
"      Shaw GM. Adverse human reproductive outcomes and electromagnetic fields: a brief summary of the epidemiologic literature. Bioelectromagnetics 2001; Suppl 5:S5.",
"     </a>",
"    </li>",
"    <li>",
"     www.iom.edu/CMS/3788/48191/68004/68230.aspx. (Accessed May 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/42\">",
"      Dunlop AL, Jack BW, Bottalico JN, et al. The clinical content of preconception care: women with chronic medical conditions. Am J Obstet Gynecol 2008; 199:S310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/43\">",
"      Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. Hum Reprod Update 1999; 5:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/44\">",
"      Solomon BD, Jack BW, Feero WG. The clinical content of preconception care: genetics and genomics. Am J Obstet Gynecol 2008; 199:S340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/45\">",
"      National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001; 108:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/46\">",
"      Cooper, WO, Hernandez-Diaz, S, Arbogast, PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 20006; 354:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/47\">",
"      Bradley KA, Badrinath S, Bush K, et al. Medical risks for women who drink alcohol. J Gen Intern Med 1998; 13:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/48\">",
"      Finkelstein JA, Davis RL, Dowell SF, et al. Reducing antibiotic use in children: a randomized trial in 12 practices. Pediatrics 2001; 108:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/49\">",
"      Scholl TO. Maternal nutrition before and during pregnancy. Nestle Nutr Workshop Ser Pediatr Program 2008; 61:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/50\">",
"      Kunz LH, King JC. Impact of maternal nutrition and metabolism on health of the offspring. Semin Fetal Neonatal Med 2007; 12:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/51\">",
"      Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr 2000; 71:1344S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/52\">",
"      Radunovic N, Kuczynski E, Rosen T, et al. Plasma apolipoprotein A-I and B concentrations in growth-retarded fetuses: a link between low birth weight and adult atherosclerosis. J Clin Endocrinol Metab 2000; 85:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/53\">",
"      Campbell DM, Hall MH, Barker DJ, et al. Diet in pregnancy and the offspring's blood pressure 40 years later. Br J Obstet Gynaecol 1996; 103:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/54\">",
"      Oakley GP Jr, Erickson JD. Vitamin A and birth defects. Continuing caution is needed. N Engl J Med 1995; 333:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/55\">",
"      Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/56\">",
"      U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/57\">",
"      Wolff T, Witkop CT, Miller T, et al. Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:632.",
"     </a>",
"    </li>",
"    <li>",
"     NHS. Vitamins and nutrition in pregnancy. file://www.nhs.uk/conditions/pregnancy-and-baby/pages/vitamins-minerals-supplements-pregnant.aspx (Accessed on November 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/59\">",
"      Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. J Obstet Gynaecol Can 2006; 28:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/60\">",
"      Nilsen RM, Vollset SE, Rasmussen SA, et al. Folic acid and multivitamin supplement use and risk of placental abruption: a population-based registry study. Am J Epidemiol 2008; 167:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/61\">",
"      Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. Placenta 1999; 20:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/62\">",
"      Hern&aacute;ndez-D&iacute;az S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/63\">",
"      Wen SW, Zhou J, Yang Q, et al. Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes. CMAJ 2008; 179:1263.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. November 30, 2010. file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx (Accessed on November 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/65\">",
"      American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 449: Maternal phenylketonuria. Obstet Gynecol 2009; 114:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/66\">",
"      Huch R, Erkkola R. Pregnancy and exercise--exercise and pregnancy. A short review. Br J Obstet Gynaecol 1990; 97:208.",
"     </a>",
"    </li>",
"    <li>",
"     Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006, 55:1-42.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/68\">",
"      Enders G, Miller E, Cradock-Watson J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/69\">",
"      Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994; 330:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/70\">",
"      Stover BH, Bratcher DF. Varicella-zoster virus: infection, control, and prevention. Am J Infect Control 1998; 26:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/71\">",
"      Smith WJ, Jackson LA, Watts DH, Koepsell TD. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 1998; 92:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/72\">",
"      Glantz JC, Mushlin AI. Cost-effectiveness of routine antenatal varicella screening. Obstet Gynecol 1998; 91:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/73\">",
"      Burgess MA, Cossart YE, Wilkins TD, et al. Varicella vaccination of health-care workers. Vaccine 1999; 17:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/74\">",
"      Coonrod DV, Jack BW, Stubblefield PG, et al. The clinical content of preconception care: infectious diseases in preconception care. Am J Obstet Gynecol 2008; 199:S296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/25/16794/abstract/75\">",
"      Zhu BP, Rolfs RT, Nangle BE, Horan JM. Effect of the interval between pregnancies on perinatal outcomes. N Engl J Med 1999; 340:589.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 448 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16794=[""].join("\n");
var outline_f16_25_16794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BARRIERS TO PRECONCEPTION COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Unplanned pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Financial issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Provider factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMPONENTS OF THE PRECONCEPTION EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Medical conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Reproductive history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Substance use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Environmental exposures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Caffeine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory assessment/screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Exposure to ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Maternal medical problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Heritable diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cessation of substance use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Depression and psychotropic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Nutrition and supplements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Immunization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Precautions against infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Insurance coverage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Other concerns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/448\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/448|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/46/23272\" title=\"figure 1\">",
"      The developing fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/448|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?29/54/30574\" title=\"form 1\">",
"      Preconceptional counseling questionnaire",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/448|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/31/32253\" title=\"table 1\">",
"      Basic medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/58/5024\" title=\"table 2\">",
"      Selected agents with potential adverse fetal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/21/34139\" title=\"table 3\">",
"      Obstetrical gynecologic history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/30/25068\" title=\"table 4\">",
"      Genetic history",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=related_link\">",
"      Alcohol intake and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7610?source=related_link\">",
"      Anaphylaxis in pregnant and breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=related_link\">",
"      Basic principles of genetic counseling for the obstetrical provider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=related_link\">",
"      Calcium physiology in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22503?source=related_link\">",
"      Cystic fibrosis: Prenatal genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=related_link\">",
"      Depression in pregnant women: Clinical features and consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30567?source=related_link\">",
"      Effect of advanced paternal age on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38217?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=related_link\">",
"      Interpregnancy interval and pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=related_link\">",
"      Intimate partner violence: Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=related_link\">",
"      Management of asthma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=related_link\">",
"      Management of epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=related_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=related_link\">",
"      Occupational and environmental risks to reproduction in females",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=related_link\">",
"      Optimizing natural fertility in couples planning pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=related_link\">",
"      Overview of occupational and environmental health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=related_link\">",
"      Physiology and clinical course of asthma in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=related_link\">",
"      Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24999?source=related_link\">",
"      Prenatal testing for the hemoglobinopathies and thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=related_link\">",
"      Prevention of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33273?source=related_link\">",
"      Risks and benefits of fish consumption and fish oil supplements during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20026?source=related_link\">",
"      The effects of caffeine on reproductive outcomes in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=related_link\">",
"      Tuberculosis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=related_link\">",
"      Weight gain and loss in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20056?source=related_link\">",
"      Work and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_25_16795="Seafood advisory for pregnant women";
var content_f16_25_16795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    United States Food and Drug Administration Advisory on Fish consumption in Pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       1. Do not eat Shark, Swordfish, King Mackerel, or Tilefish because they contain high levels of mercury.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       2. Eat up to 12 ounces (2 average meals) a week of a variety of fish and shellfish that are lower in mercury.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &bull; Five of the most commonly eaten fish that are low in mercury are shrimp, canned light tuna, salmon, pollock, and catfish.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &bull; Another commonly eaten fish, albacore (\"white\") tuna has more mercury than canned light tuna. So, when choosing your two meals of fish and shellfish, you may eat up to 6 ounces (one average meal) of albacore tuna per week.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Check local advisories about the safety of fish caught by family and friends in your local lakes, rivers, and coastal areas. If no advice is available, eat up to 6 ounces (one average meal) per week of fish you catch from local waters, but don't consume any other fish during that week.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Note: although not specifically mentioned in the advisory, herring, Atlantic mackerel, and sardines are also low in mercury but high in n-3 long chain polyunsaturated fatty acids.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: What fish should pregnant women avoid? Available at",
"     <a href=\"file://www.fda.gov\">",
"      www.fda.gov",
"     </a>",
"     . Last update 11/23/2009",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16795=[""].join("\n");
var outline_f16_25_16795=null;
var title_f16_25_16796="PCV7 to PCV13 transition";
var content_f16_25_16796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended transition schedule from 7-valent pneumococcal conjugate vaccine (PCV7) to 13-valent vaccine (PCV13) vaccination among infants and children, according to number of previous PCV7 doses received - Advisory Committee on Immunization Practices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Infant series",
"       </td>",
"       <td class=\"subtitle1\">",
"        Booster dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Supplemental PCV13 dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        2 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        4 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        6 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        &ge;12 months*",
"       </td>",
"       <td class=\"subtitle2\">",
"        14 to 59 months",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV13",
"       </td>",
"       <td>",
"        PCV13",
"       </td>",
"       <td>",
"        PCV13",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV13",
"       </td>",
"       <td>",
"        PCV13",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV13",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV7",
"       </td>",
"       <td>",
"        PCV13",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * No additional PCV13 doses are indicated for children age 12 to 23 months who have received 2 or 3 doses of PCV7 or PCV13 before age 12 months and at least 1 dose of PCV13 at age &ge;12 months.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      For children with underlying medical conditions, a single supplemental PCV13 dose is recommended through age 71 months. Underlying medical conditions include chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure), chronic lung disease (including asthma if treated with prolonged high-dose oral corticosteroids), diabetes mellitus, cerebrospinal fluid leaks, cochlear implant, children with functional or anatomic asplenia, and children with immunocompromising conditions.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59:260.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16796=[""].join("\n");
var outline_f16_25_16796=null;
var title_f16_25_16797="Mortality per 1000 live births by plurality";
var content_f16_25_16797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75320%7EOBGYN%2F60676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75320%7EOBGYN%2F60676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infant, neonatal, postnatal mortality per 1000 live births by plurality",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infant deaths",
"        <br/>",
"        (birth to 1 year)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neonatal deaths",
"        <br/>",
"        (birth to day 28)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Postneonatal",
"        <br/>",
"        (day 29 to 1 year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Singletons",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        11.2",
"       </td>",
"       <td class=\"centered\">",
"        7.8",
"       </td>",
"       <td class=\"centered\">",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Twins",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        66.4",
"       </td>",
"       <td class=\"centered\">",
"        55.9",
"       </td>",
"       <td class=\"centered\">",
"        10.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Triplets",
"        </strong>",
"        *",
"       </td>",
"       <td class=\"centered\">",
"        190.4",
"       </td>",
"       <td class=\"centered\">",
"        168.8",
"       </td>",
"       <td class=\"centered\">",
"        21.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Triplets and higher order multiple gestations.",
"     <br/>",
"     Calculated from US Vital Statistics, 1998 and from US Public Health Service. Healthy People 2000: National Health Promotion and Disease Prevention Objectives, DHHS Pub. No. (PHS)90-50212. Washington, DC: US Department of Health and Human Services, Public Health Service; 1990.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Oleszczuk JJ, Oleszczuk AK, Keith LG. Twin and triplet birth: facts, figures, and costs. Female patient 2003; 28:11. Copyright &copy; 2003 Jaroslaw J Oleszczuk, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gestational age and birthweight characteristics of United States singleton, twin, and triplet live births",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Singletons",
"        <br/>",
"        (1995)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Twins",
"        <br/>",
"        (1991-1995)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Triplets",
"        <br/>",
"        (1991-1995)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         No. of births",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        3,603,971",
"       </td>",
"       <td class=\"centered\">",
"        463,856",
"       </td>",
"       <td class=\"centered\">",
"        18,843",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mean gestational age (wk)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        39.03",
"       </td>",
"       <td class=\"centered\">",
"        35.77",
"       </td>",
"       <td class=\"centered\">",
"        32.48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Percent very preterm (&lt;33 wk)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        1.70",
"       </td>",
"       <td class=\"centered\">",
"        13.94",
"       </td>",
"       <td class=\"centered\">",
"        41.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Percent preterm (&lt;37 wk)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        9.43",
"       </td>",
"       <td class=\"centered\">",
"        50.74",
"       </td>",
"       <td class=\"centered\">",
"        91.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Birthweight (g)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        3357",
"       </td>",
"       <td class=\"centered\">",
"        2389",
"       </td>",
"       <td class=\"centered\">",
"        1735",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Percent very low birthweight (&lt;1500 g)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        1.10",
"       </td>",
"       <td class=\"centered\">",
"        10.12",
"       </td>",
"       <td class=\"centered\">",
"        31.88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Percent low birthweight (&lt;2500 g)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        6.06",
"       </td>",
"       <td class=\"centered\">",
"        52.24",
"       </td>",
"       <td class=\"centered\">",
"        91.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Percent small for gestational age",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        9.38",
"       </td>",
"       <td class=\"centered\">",
"        35.63",
"       </td>",
"       <td class=\"centered\">",
"        36.57",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Oleszczuk JJ, Oleszczuk AK, Keith LG. Twin and triplet birth: facts, figures, and costs. Female patient. 2003; 28:11. Copyright &copy; 2003 Jaroslaw J Oleszczuk, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16797=[""].join("\n");
var outline_f16_25_16797=null;
var title_f16_25_16798="Causes constipation children";
var content_f16_25_16798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57393%7EPEDS%2F64759%7EPEDS%2F82181%7EPEDS%2F61392%7EPEDS%2F55786%7EPEDS%2F70206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57393%7EPEDS%2F64759%7EPEDS%2F82181%7EPEDS%2F61392%7EPEDS%2F55786%7EPEDS%2F70206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of constipation in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Most common causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Painful defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Causes not to miss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infantile botulism (constipation an early complaint, facial and ocular palsies, poor suck and hypotonia are other features)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal dysraphism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypokalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hirschsprung's disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p. 518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic causes of constipation in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Type of formula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cow's milk intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low dietary fiber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inadequate&nbsp;fluid intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hot weather",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia nervosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Starvation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnoses to consider in infants and children with delayed passage of meconium",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hirschsprung disease",
"       </td>",
"       <td>",
"        Abdominal distension and vomiting are common. On digital examination, the rectal vault may be empty. On contrast enema, a transition zone may be seen, but often is not visible in newborns.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intestinal obstruction",
"       </td>",
"       <td>",
"        Consider atresia, webs or volvulus. Obstruction may be present even in infants who pass meconium.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meconium ileus",
"       </td>",
"       <td>",
"        Symptoms often begin on second day of life. Most patients with meconium ileus have cystic fibrosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional ileus",
"       </td>",
"       <td>",
"        Occurs in setting of prematurity, sepsis, respiratory distress, pneumonia, or electrolyte disturbances.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small left colon*",
"       </td>",
"       <td>",
"        Barium enema shows small-caliber left colon. Increased incidence with maternal diabetes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs administered to mother before delivery",
"       </td>",
"       <td>",
"        Magnesium sulfate (MgSO4), opiates, or ganglionic blocking agents.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"       <td>",
"        Infants with hypothyroidism also may have prolonged jaundice, lethargy, and low body temperature.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Similar findings may occur in infants with Hirschsprung disease (HD), so affected infants should be observed closely and evaluated for HD if appropriate.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurogenic causes of constipation in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Cerebral palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelomeningocele",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal cord injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sacral agenesis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Split spinal cord malformation (diastematomyelia)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal dysraphism (several types; sometimes associated with cutaneous anomalies overlying the dysraphic segment, and/or with tethered cord syndrome)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurofibromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscular weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guillaine-Barre' syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuronal dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial dysautonomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acquired postganglionic cholinergic dysautonomia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Refer to UpToDate topic review on Spinal dysraphism.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd edition, Lippincott, Williams &amp;Wilkins, Philadelphia 1999. p.518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of voluntary stool withholding in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Painful defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anal fissure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Perianal irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sexual abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemorrhoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Change of enviroment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        New school, traveling, or other change in routine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Family stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improper toilet training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emotional disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe mental retardation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Endocrine and metabolic causes of constipation in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Hypokalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypo- or hypercalcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyuria (leading to dehydration)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute intermittent porphyria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16798=[""].join("\n");
var outline_f16_25_16798=null;
var title_f16_25_16799="Diffuse episcleritis";
var content_f16_25_16799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse episcleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Monocular attack of diffuse episcleritis in a patient with relapsing polychondritis. There is diffuse injection of the episcleral vessels, but the underlying sclera is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_25_16799=[""].join("\n");
var outline_f16_25_16799=null;
